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ABSTRACT 
The human polyomavirus JC (JCPyV) is the causative agent of the fatal demyelinating disease 
progressive multifocal leukoencephalopathy (PML). While the archetypal form of the virus is 
ubiquitous in the healthy human population, it is the rearranged form that is responsible for 
PML. The archetype form of JCPyV has a conserved noncoding control region (NCCR) that is 
defined by six designated blocks, A-F. However, the rearranged form has deletions and/or 
duplications in its NCCR. Although it has been established that the rearranged form of JCPyV is 
pathogenic, the events leading to the reactivation and/or rearrangement in its NCCR have yet to 
be determined. Thus, the lack of in vitro and in vivo archetype JCPyV replication models have 
hindered the understanding of mechanisms underlying the development of PML pathogenesis. 
In this report, we demonstrate in vitro infection and efficient replication of archetype JCPyV in 
renal proximal tubule epithelial (RPTE) and human brain microvascular endothelial (HBMVE) 
cells, limited or no replication in human brain cortical astrocytes (HBCA) and primary human 
fetal glial (PHFG) cells, and in vitro rearrangement of archetype JCPyV at day 645 in COS-7 
cells. In addition, we demonstrate that archetype JCPyV (CY) and rearranged JCPyV (Mad1) 
can replicate in HBMVE cells, while limited replication was observed when HBMVE cells were 
transfected with the hybrid JCPyV (CYrM1c). Lastly, we demonstrate in vivo infection of JCPyV 
in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. To our knowledge, this is the first study 
demonstrating the ability for urine-derived archetype JCPyV to rearrange in vitro, to be 
infectious in naïve primary cells, and to demonstrate JCPyV infection in humanized NSG mice. 
This study will therefore give insight on cellular conditions involved in urine-derived archetype 
JCPyV infection, reactivation, and rearrangement, which will impact the development of much-
needed therapeutics for PML. 
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JC VIRUS AND HUMAN DISEASE 
JCPyV 
JC virus (JCPyV), a neurotropic human polyomavirus belonging to the genus 
Orthopolyomavirus in the family Polyomaviridae, was first isolated in 1971 from the brain of 
John Cunningham, a patient suffering from progressive multifocal leukoencephalopathy (PML), 
for whom the virus is named (183). Polyomaviruses have been found in humans, monkeys, 
rodents and birds (48, 105). According to the International Committee on Taxonomy of Viruses, 
the family Polyomaviridae consists of three genera Orthopolyomavirus with the species simian 
vacuolating virus 40 (SV40), Brennan Krohn polyomavirus (BKPyV), and JCPyV; 
Wukipolyomavirus with Karolinska Institute polyomavirus (KIPyV) and Washington University 
polyomavirus (WUPyV); and Avipolyomavirus with respective PyVs infecting birds (Fig.1) (111) .  
In addition to JCPyV, the polyomaviruses that have the ability to infect humans include BKPyV, 
KIPyV, WUPyV and Merkel cell polyomavirus (MCPyV), Trichodysplasia spinulosa-associated 
polyomavirus (TSPyV), human polyomavirus 6, 7, and 9 (HPyV6, HPyV7, and HPyV9), and 
Malawi polyomavirus (MWPyV) (117, 231). The prototype nonhuman primate polyomavirus, 
simian vacuolating virus 40 (SV40), is also known to rarely infect humans. 
 
Like other tumor viruses in the family Polyomaviridae, JCPyV is non-enveloped with an 
icosahedral capsid containing a small, circular, double-stranded DNA genome. JCPyV virions 
measure approximately 40-45 nm in diameter and it’s circular double-stranded DNA genome is 
5.1 kb (147). The single negatively super coiled double-stranded DNA is associated with host 
cell histones to form mini-chromosomes.  
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Figure 1. Phylogenetic tree of Polyomaviridae:  The phylogenic relationships among the 
Polyomaviridae family was constructed based on whole genomic nucleotide sequences (99). 
The mammalian polyomaviruses include the genera Orthopolyomavirus and Wukipolyomavirus, 
while polyomaviruses infecting birds are grouped under the Avipolyomavirus genus. JC 
polyomavirus (JCPyV), BK polyomavirus (BKPyV), Simian virus 40 (SV40), Baboon 
polyomavirus I (SA12), California sea lion polyomavirus (SLPyV), Bat polyomavirus (BatPyV), 
Murine pneumotropic virus (MPtV), Squirrel Monkey polyomavirus (SqPyV), Bovine 
polyomavirus (BPyV), Bornean orangutan polyomavirus (OraPyVI), Tricodysplasia spinulosa-
associated polyomavirus (TSPyV), B-lymphotropic polyomavirus (LPyV), Hamster polyomavirus 
(HaPyV), Murine polyomavirus (MPyV), Sumatran orangutan polyomavirus (OraPyV2), Merkel 
cell polyomavirus (MCPyV), Human polyomavirus 6 (HPyV6), Human polyomavirus 7 (HPyV7), 
Karolinska Institute polyomavirus (KIPyV), Washington University polyomavirus (WUPyV), 
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Goose hemorrhagic polyomavirus (GHPyV), Crow polyomavirus (CPyV), Canary polyomavirus 
(CaPyV), Finch polyomavirus (FPyV), Avian polyomavirus (APyV) 
  
JCPyV’s circular genome is functionally divided into three regions:  the early coding region, the 
late coding region and the non-coding control region (NCCR) or regulatory region (Fig.2) (145). 
Transcription of the early and late coding regions begin at the  NCCR (0.4 kb), where early 
transcription proceeds in a counterclockwise direction and late transcription proceeds clockwise 
on the opposite strand of the DNA (117). The NCCR encompasses the origin of replication (ori), 
viral promoter-enhancing sequences, and the transcriptional control region (TCR), which act as 
binding sites for cell transcription factors (43).   
 
The early region (2.4 kb) encodes the transforming proteins, large T and small t antigens, which 
are involved in gene regulation, viral replication and important in promoting transformation of 
cells in culture and oncogenesis in vivo (117, 230); along with the recently described T’ proteins 
generated by alternative splicing of the early mRNA.  
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Figure 2. JCPyV genome:  (A) The JC virus circular double stranded DNA genome is 5.13 Kb 
and consists of three regions:  the early coding region, the late coding region, and the non-
coding control region (NCCR) or regulatory region (78, 84). (B) The archetype NCCR is usually 
found in the kidney and urine of both healthy and immunosuppressed individuals. Rearranged 
strains are characterized by having deletions, duplications, and/or tandem repeats in their 
NCCRs, and are most commonly found in the brain or cerebrospinal fluid of PML patients.  
 
A 
B 
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The late region (2.3 kb) encodes the major viral capsid protein VP1 which mediates cell 
attachment, the minor capsid proteins VP2 and VP3, and the accessory agnoprotein (43). The 
early and late coding regions are highly conserved and have not been convincingly associated 
with disease pathogenesis (230). They do however, make up about 90% of the viral genome 
and confer the genotype that is associated with the various subtypes that can be found in 
different geographical areas (230). 
 
Based upon the structure of the NCCR, two types of JCPyV have been identified in human 
tissues. The sequence of the regulatory region is known as the “archetype”,  because it is 
thought that all other forms of JCPyV have evolved from it (260).  Archetype JCPyV is found in 
the kidneys and urine of healthy individuals as well as those affected with PML (139, 260) and it 
is this type that is thought to circulate in the human population. Little sequence variation exists 
in the genomes of independent isolates of archetype JCPyV (259, 260). It has been suggested 
that the rearranged form is generated by sequence rearrangements within the archetype NCCR 
during viral replication, yielding a new, potentially more active form of the virus (50). The 
regulatory region of JCPyV most often isolated from CSF and brain of patients with PML has 
rearrangements, including duplications, tandem repeats, insertions and deletions (Fig.3). The 
rearranged form can also be detected in brain, tonsil and lymphocytes in people with and 
without PML (81, 213).  The differences in cellular tropism of both archetype and rearranged 
JCPyV in PML and non-PML patients are summarized in Table 1.  
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Figure 3. Structural arrangements of various JCPyV NCCRs:  Vertical numbers above the 
diagram indicate the nucleotide position according to the numbering system described in 
Frisque et al. 1984 (79). Horizontal numbers indicate the number of nucleotides defined in each 
block of the NCCR archetype region, with the TATA box contained in the 25-bp region. The CY 
strain of JCPyV was first isolated from the urine of a healthy individual and described by Yogo et 
al., 1990 (260). Mad1, Mad4, Mad11Br, and Mad8Br are naturally occurring strains isolated 
from PML brain tissue described by Padgett et al. 1971 (183) and Grinnell et al. 1983 (90). 
CYΔ23, CYΔ66, and MΔ198 are laboratory constructs (49). Sequences that are identical to the 
CY strain are represented by solid horizontal lines, deleted sequences by gaps between lines, 
and duplications by parallel lines. Repeated sequences are read from the beginning of the 
sequence from the left and continues to the right before continuing at the left of the second line. 
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Table 1. JCPyV tropism in PML and non-PML patients 
 
Non-PML patients 
 
References 
 
PML patients 
 
References 
Archetype JCPyV in 
urine 
 
Kitamura et al. 
(1990) (121), 
Markowitz et al. 
(1993) (155), 
Omodeo-Zorini et al. 
(2003) (180) 
Archetype JCPyV in 
urine 
 
Dorries et al. 
(1983) (55), 
White et al. 
(1992) (250) 
 
 
 
 
 Archetype and 
rearranged JCPyV in 
bone marrow 
Marzocchetti et al. 
(2008) (159) 
  Rearranged JCPyV 
in plasma 
Fedele et al. 
(2003) (66) 
Archetype JCPyV in B 
lymphocytes 
 Archetype JCPyV in 
B lymphocytes 
Houff et al. 
(1988) (102) 
Rearranged JCPyV in 
lymphocytes* 
Tornatore et al. 
(1992) (234) 
Rearranged JCPyV 
in lymphocytes 
Tornatore et al. 
(1992) (234) 
Archetype JCPyV in 
kidneys 
 
Chesters et al. 
(1983) (39), 
Kitamura et al. 
(1997) (123) 
  
Archetype JCPyV in 
gastrointestinal tract 
 
Laghi et al. 
(1999) (131), 
Selgrad et al. 
(2009) (211), 
Ricciardiello et al. 
(2000) (193) 
  
Archetype JCPyV in 
tonsillar tissue  
 
Goudsmit et al. 
(1981) (88), 
Kato et al. 
(2004) (112) 
  
Archetype JCPyV in 
brain 
White et al. 
(1992) (250), 
Perez-Liz et al.  
(2008) (186) 
Archetype and 
rearranged JCPyV in 
brain 
 
White et al. 
(1992) (250), 
Tan et al. 
(2010) (229) 
Archetype JCPyV in 
CNS and CSF* 
 
Vago et al. 
(1996) (237) 
Rearranged JCPyV 
in the CNS and CSF 
Vago et al. 
(1996) (237), 
Fedele et al.l 
(2006) (67) 
*HIV-1 positive patients without PML 
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JCPyV transmission and epidemiology 
Although JCPyV is widespread throughout the human population, the mechanism of human-to-
human transmission of JCPyV is poorly understood. Seroepidemiological data indicate that 
JCPyV infection occurs during childhood and is typically subclinical (182). Furthermore, about 
80-85% of the adult population have  antibodies against JCPyV, which implies previous 
exposure and a possible latent infection (83, 150).  It is known that JCPyV is excreted and found 
in sewage which suggests oral ingestion and inhalation of contaminated material as a possible 
entry of JCPyV into the human population (19, 169). Recent environmental studies 
demonstrated detection of human polyomaviruses (HPyV) in almost all types of environmental 
water, including wastewater (25, 120), costal seawater (171), storm water (218), river water (26, 
93, 97), and drinking water sources (2).  
 
A possible means by which JCPyV enters and spreads in the body is via the infection of tonsil 
cells. It is presumed that via infected tonsil cells, JCPyV subsequently spreads elsewhere by 
replication in lymphoid cells (169). Because asymptomatic shedding of JCPyV in the urine can 
be seen in both healthy individuals and immunosuppressed patients (4) the kidney is thought to 
be the major organ of JCPyV persistence during latency (39). After initial infection, the virus 
disseminates and establishes a persistent infection in the kidney throughout life. It is thought 
that upon reactivation, JCPyV enters the brain via a Trojan horse mechanism via B 
lymphocytes.  
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JCPyV life cycle 
JCPyV infects cells by first binding to a receptor on the outer membranes of susceptible cells. 
JCPyV possess intrinsic hemagglutination activity which allows it  to engage alpha 2-3- and/or 
alpha 2-6-linked sialic acid residues, suggesting binding to oligosaccharide as an important step 
in JCPyV infection (136). It has also been shown that JCPyV can interact with the serotonin 
receptor 2A (5HT2AR) (62), which leads to virus internalization into glial cells. Virus is taken up 
by clatherin-dependent endocytosis (10) followed by its transportation to the nucleus where the 
removal of the viral capsid proteins occurs. Early transcription results in a primary transcript that 
is alternatively spliced into two mRNAs which code for the large T-antigen (TAg), a nuclear 
phosphoprotein that is essential for viral DNA replication, and the small t-antigen (117). TAg 
complexes with host DNA polymerase α and the replication protein-A at the origin of DNA 
replication to promote DNA synthesis (18). Once TAg initiates DNA replication and stimulates 
transcription from the late promoter the late phase of the viral lifecycle begins. JCPyV relies on 
host cell enzymes and cofactors for DNA replication. Since expression of these proteins are 
confined to the S-phase of the cell cycle, TAg stimulates the cell cycle by modulating cellular 
signaling pathways via binding key cellular control proteins including p53, pRb, and IRS-1, for 
example (253). Hsp70 interacts with VP2, VP3, and TAg and accumulates in the nucleus of 
infected cells. Association of VP2, VP3, and TAg though their DNA binding domains results in 
enhancing TAg binding to the origin of replication subsequently inducing JCPyV viral DNA 
replication (208). Ultimately, the capsid proteins, VP1, VP2 and VP3, are expressed from the 
late region and assemble with the replicated viral DNA to form intranuclear virions, which are 
released upon cell lysis (60, 117) (Fig.4).  
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Figure 4. Life cycle of JCPyV: [1] The lifecycle starts when virus attaches to a cellular receptor 
complex. [2] Following this initial interaction, virus internalization into the cytosol happens via 
clatherin-dependent endocytosis. [3] Nuclear transport occurs where [4] uncoating happens 
thereafter to expose the genome for [5] early gene expression. [6] Viral DNA synthesis precedes 
[7] late gene expression. Finally, new virions are [8] assembled, which are released, thus 
marking the successful completion of productive infection (60).  
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JCPyV persistence and latency 
JCPyV is excreted in the urine of healthy persons and in patients with PML. JCPyV remains 
latent in the kidneys, lymph nodes, and bone marrow of healthy and immunosuppressed 
individuals without PML and, upon reactivation, can cause a lytic infection of oligodendrocytes in 
the brain, leading to PML (229). It has also been detected in renal tissue, including that of 
healthy persons (39). These data suggest that the kidney serves as a site of latent infection, but 
the mechanisms and/or biochemical events that allow this are unclear (203). Bone marrow is 
another possible site for JCPyV latency. Susceptibility of infection has been demonstrated in 
both a CD34+ hematopoietic progenitor cell line, KG-1, and in primary cells (167). In addition, a 
current study by Tan et al. (229) suggests that JCPyV can spread throughout the body in 
immunosuppressed and immunocompetent individuals alike and that it is present in the brains 
of individuals without PML (Fig.5). The ability for JCPyV to persist for life in an infected host is a 
common characteristic of many DNA viruses, including herpesviruses, adenoviruses, and other 
polyomaviruses (20, 107). In a persistent infection, viral replication is kept in check by the host’s 
immune system resulting in either a low or absent replication state. In doing so the virus has 
developed mechanisms to evade the immune system, allowing it to coexist with the host.  
13 
 
 
Figure 5. JCPyV dissemination and pathogenesis of PML:  The events thought to occur 
during the JCPyV life cycle and pathogenesis of PML are shown with the common 
nonpathogenic events labeled in blue and the rare pathogenic events in red. Virions are thought 
to be transmitted through sewage contaminated material by inhalation or ingestion via the 
mouth and nose, [1] top right-hand corner, of predominantly archetype JCPyV (blue), but 
occasionally the neurotropic form (red). [2] It is thought to enter the bloodstream through either 
14 
 
the epithelium of the tonsils and the upper respiratory tract or [3] the gastrointestinal tract [4] to 
establish primary viremia . Currently, the nature of primary JCPyV viremia is not well 
understood, but [5] it has been suggested that virus may exist as free virions and/or as white 
blood cell-associated virus . [6] Virus is thought to spread to the kidney and other organs via a 
hematogenous route. [7] In the kidney, JCPyV can replicate sporadically and at low levels in the 
epithelium of the kidney tubules, from where it can shed from the apical face of the kidney 
epithelium. This shedding can lead to viruria and transmission of infectious virions via urine, 
completing the JCPyV lifecycle. [8] It is thought that virus can also spread to the bone marrow, 
where it has been speculated but not proven that neurotropic virus (red) can emerge by an 
unknown mechanism. [9] JCPyV may also undergo hematogenous spread from the bone 
marrow and possibly other locations in association with leukocytes, [10] including the brain, 
where neurotropic JCPyV DNA can be detected in healthy, immunocompetent individuals in the 
absence of expression of detectable levels of viral proteins. [11] Under immunosuppression , 
neurotropic JCPyV can become reactivated, undergo transcription and DNA replication, and 
spread to form microlesions, which can coalesce, increase in size, and result in PML. The 
pathological features of PML are shown in the bottom panels (left to right) T2-weighted MRI 
showing hyperintense signal abnormalities in the white matter of the parieto-occipital lobes, H 
and E staining demonstrating oligodendrocytes bearing nuclear inclusion bodies (upper arrow) 
and bizarre astrocytes (lower arrow), and TEM of PML tissue showing crystalline arrays of 45 
nm viral particles within a nuclear inclusion body (256). 
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JCPyV reactivation and rearrangement 
Although the prevalence of archetype JCPyV infection in the general population is high, the 
incidence of JCPyV PML in immunocompetent individuals is absent, indicating stringent immune 
mechanisms to prevent reactivation and disease in an immunocompetent host. The site and 
modality of JCPyV reactivation and rearrangement has yet to be conclusively described, 
although immunosuppression is a major component. The most likely hypothesis is that virus 
reactivation occurs in the periphery, where it infects circulating B lymphocytes, and through a 
Trojan horse mechanism these JCPyV-infected cells cross the blood-brain barrier to enter the 
central nervous system (CNS) where JCPyV infects astrocytes. JCPyV infection is usually 
restricted by the actions of the immune system, most notably cell-mediated immunity, where it is 
thought that there is an association between a defect in the generation of cytotoxic T cells and 
the reactivation of JCPyV from latency to cause PML (83, 128). Dormant JCPyV contains the 
archetype NCCR and has been described as predominantly associated with peripheral organs, 
including the tonsils, kidneys, spleen, and bone marrow. Whether archetype JCPyV is present in 
the CNS in immunocompetent individuals remains controversial (123, 185). Conversion of non-
pathogenic archetype JCPyV to the neurotropic PML-causing JCPyV involves rearrangements 
in the NCCR, which regulates JCPyV transcription and DNA replication. However, the 
mechanism(s) by which JCPyV undergoes NCCR sequence alterations has yet to be described. 
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PML associated JCPyV VP1 mutations  
Mutations in the major viral capsid protein 1 (VP1) of JCPyV have been suggested to favor the 
onset of PML. Several studies have reported the presence of several mutations in VP1 from 
JCPyV isolated from PML patients. These nonpolymorphic (i.e. JCPyV subtype-independent) 
PML-associated mutations or deletions of JCPyV VP1 include amino acids at positions 50, 51, 
55, 60, 61, 122-125, 265, 267, 269, 271, and 283 (113, 262, 263). These studies suggest that 
the role of VP1 in PML pathogenesis might be attributed to its direct interaction with host 
immune responses, as well as cell attachment and viral entry via sialic acid receptors on 
susceptible cells (36, 135, 174). Thus, the virulence of PML associated JCPyV can be a result 
from changes in the affinity and specificity of the virus via its viral capsid for its cellular 
receptor(s) which directly affect viral infectivity and transmission. 
 
PML, an always-fatal demyelinating disease of the CNS, is characterized by multiple foci of 
demyelination caused by the lytic infection of JCPyV infected oligodendrocytes (86, 116, 150, 
194). PML was first described by Astrom et al. in 1958 (5), in a patient with lymphatic leukemia 
and a patient with Hodgkin’s disease. Although viral etiology for PML was proposed by 
Cavanagh et al. in 1959 (29) and Zu Rhein and Chou demonstrated viral particles resembling 
Papovaviruses in 1965 via electron microscopy (265), it wasn’t until 1971 that Padgett et al. 
cultivated JCPyV from the brain of a PML patient [1], where the virus was ultimately named after 
the initials of the patient. From 1958 to the 1980s, PML was primarily observed in patients 
treated with corticosteroids, other immunosuppressive drugs, and chemotherapy (134). It wasn’t 
until the 1980s when PML became predominantly associated as a complication related to AIDS 
patients. Recently, the use of immunomodulatory and immunosuppressive drugs may increase 
the risk of development of PML in the setting in these immunosuppressive conditions (17). 
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Clinical and pathological features of PML 
Primary JCPyV infection is typically subclinical (182), PML develops only in individuals with 
severely impaired immune systems, such as AIDS patients (117). PML has most often 
presented as an opportunistic infection in HIV patients with lymphopenia but recently it has been 
seen in patients treated with immunosuppressive drugs (22), including natalizumab, a 
monoclonal antibody (mAb) used to treat multiple sclerosis (MS) .  
 
The onset of PML is insidious, but in the absence of treatment, disease progression is usually 
rapid, with death ensuing in 3 to 6 months after diagnosis. The clinical features of PML vary 
according to the localization of the demyelinating lesion and are non-specific. The 
periventricular and sub-cortical regions of the parieto-occipital and frontal lobes of the brain are 
the most affected regions (254). Common presenting symptoms include cognitive deficits, gait 
disorders, limb weaknesses, speech disorders and visual impairments (14, 64, 65).The 
pathogenesis of PML can be divided into 3 phases, with the first phase being a primary clinically 
inapparent infection. In the second phase, it has been suggested that  a persistent and latent 
peripheral infection occurs within the urinary tract, bone marrow, and probably the spleen (244). 
The third and final phase is probably induced by immunologic and molecular alterations of the 
viral NCCR (245)  resulting in reactivation of archetype JCPyV to the virulent rearranged 
JCPyV. Although the rearrangement of the NCCR of archetype JCPyV is thought to be an 
important event in the pathogenesis of PML, little is known about what induces this 
rearrangement. In addition, it is not known whether JCPyV is present in a latent state in the 
brain or whether it enters only after reactivation has occurred elsewhere in the periphery.  
 
The neuropathological hallmarks of PML consist of multifocal microscopic and macroscopic 
demyelinating lesions that tend to coalesce in the subcortical white matter near the gray-white 
matter junction. Oligodendrocytes sustain productive lytic infection and when infected with 
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JCPyV, their nuclei become enlarged and filled with eosinophilic inclusion bodies. In addition, 
bizarre astrocytes appear enlarged, with multiple or multilobate hyperchromatic nuclei, at times 
resembling neoplastic cells (44) (Fig.6 and 7).  
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Figure 6. Histological features of PML: (a) Multiple areas of demyelination or plaques are 
observed at low magnification in paraffin-embedded sections of PML brain tissue stained with 
luxol fast blue. (b)  Bizarre, transformed reactive astrocytes that may be multinucleated and 
resemble neoplastic cells are frequently observed in PML lesions. (c) Residual JCPyV-infected 
oligodendrocytes harboring intranuclear eosinophilic inclusion bodies can be seen with 
demyelinated plaques. (d)  Electron microscopy of oligodendrocyte inclusions reveals the 
presence of 45 nm icosahedral viral particles in the nucleus consistent with JC virions (115).  
 
20 
 
 
Figure 7. Brain lesions and cell types infected by JCPyV: The classical description of PML 
indicates demyelinating lesions of JCPyV infected oligodendrocytes and astrocytes located in 
the white matter of the cerebrum or the cerebellum. More recently, descriptions of lesions found 
in the cerebral cortex or at the gray matter-white matter junction with JCPyV-infected neurons 
have been described. When JCPyV infection occurs in granule cell neurons, cerebellar atrophy 
can occur (84). 
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PML in HIV/AIDS patients 
Prior to the 1980s, PML was considered an extremely rare opportunistic infection; the incidence 
of PML was 0.15 cases per million population. However, the HIV pandemic led to a new subset 
of immunosuppressed individuals, resulting in a dramatic increase in the prevalence of PML to 
0.6 cases per million (100). Currently, the most common predisposing factor for symptomatic 
JCPyV infection is HIV-induced immunodeficiency, with about one in 20 HIV-infected persons 
developing PML (8, 15, 16). The increased frequency of PML among patients with AIDS when 
compared to other immunocompromised patients suggests that the presence of HIV-1 in the 
brain of infected individuals is closely associated with the pathogenesis of AIDS-related PML 
(178). Thus, the significantly longer survival times reported for PML patients treated with highly 
active antiretroviral therapy (HAART) are primarily due to the successful reduction of HIV viral 
loads and resulting immunosuppression (244). The introduction of HAART has led to a 
significant prolonged median survival time, with AIDS patients living 4.5 years if their CD4+ cell 
counts >100 cells/µL after diagnosis of PML. This is in contrast to the median survival time 3.4 
years for those with CD4+ cell counts <100 cells/µL after PML diagnosis (14). Although HIV 
accounts for an overwhelming majority of PML cases, in the order of 80%, there is increasing 
incidence of non-HIV related PML cases (98) (Fig.8).  
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Figure 8. Occurrence of PML in the United States: The Venn diagram depicts the occurrence 
of PML, seen in the gold circles, in different populations of the United States. The outer circle 
represents the total population in 2012, which was 314 million individuals. The outer black ring 
represents the majority of healthy individuals in the population. This group of healthy individuals 
refer to those with no apparent case of immunosuppression and include the elderly, patients 
with chronic liver or kidney disease, and those with idiopathic or transient lymphocytopenia. The 
purple circle refers to a subpopulation of individuals who have impaired cell-mediated immunity 
(CMI), including, cancer survivors, bone marrow and solid transplant recipients, individuals 
suffering from rheumatoid arthritis treated with immunosuppressive agents like rituximab, and 
multiple sclerosis (MS) patients treated with natalizumab, fingolimod, or dimethyl fumurate. 
Lastly, the inner red circle represents individuals with impaired CMI due to HIV-1 infection/ 
AIDS, approximately 1.2 million individuals (256). 
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PML in HIV-uninfected individuals  
The incidence of PML in HIV-uninfected individuals has increased with the broader use of 
immunosuppressive and immunomodulatory drugs used to treat an array of systemic and 
neurologic autoimmune disorders. These agents include, but are not limited to, chemotherapies, 
rheumatologic disease-modifying therapies, and multiple sclerosis (MS) treatments, which result 
in a decrease in immune surveillance of the CNS and therefore an increased risk of PML. PML 
has been associated with a variety of medications including alemtuzumab, belatacept, dimethyl 
fumurate, eculizumab, brentuximab, fingolimod, fludaribine, infliximab, leflunomide, 
mycophenolate mofetil, natalizumab, rituximab, among others. 
 
In recent years, monoclonal antibodies (mAbs) have been used to treat a wide spectrum of 
immunological diseases. A resurgence of PML occurred in the 2000s as a result of the use of 
immunomodulatory compounds like the monoclonal antibodies natalizumab, efalizumab, and 
rituximab for the treatment of autoimmune diseases, including multiple sclerosis, Crohn’s 
disease, severe forms of plaque psoriasis, hematologic malignancies, and rheumatoid arthritis 
(148). Some mAbs suppress the immune system and, as a result, predispose patients to PML 
(8). In 2005, PML developed in MS patients treated with the mAb natalizumab, trade name 
Tysabri (244), which is directed against the α4-integrin of the cell adhesion molecule family (8) 
(Fig.9).  
 
In addition, hematologic malignancies, immunodeficiency disorders, idiopathic lymphopenia, 
and autoimmune rheumatologic disorders can lead to an increased risk of PML in the absence 
of pharmacologic therapies, which is likely due to the aberrant immune function associated with 
these conditions (210). Particular among autoimmune diseases, systemic lupus erythematosus 
(SLE) is associated with an increased risk of PML even in the absence of immunosuppression.  
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Figure 9. Natalizumab induced PML in MS patients: This figure summarizes three current 
hypotheses of how natalizumab may lead to PML. (a) Natalizumab may prevent entry of JCPyV-
specific cytotoxic T cells into the brain, which are necessary to control latent JCPyV infected 
oligodendrocytes. (b) Natalizumab inhibits VLA-4-dependent homing and retention of 
lymphocytes in the bone marrow, a possible site of JCPyV latency, therefore resulting in an 
increase of JCPyV-infected peripheral leukocyte population. Lastly, it has been suggested that 
natalizumab-induced expression of Spi-B, a transcription factor associated with increased 
JCPyV transcription (54). 
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PML in immunologically normal individuals  
PML is described as affecting individuals with severe immunosuppression such as HIV/AIDS, 
those receiving immunosuppressant therapy, those with hematological malignancy, and organ 
transplant recipients. Descriptions of PML in immunologically healthy individuals have been 
described in case reports, however, these individuals are described as being immunologically 
normal and immunocompetent in the context of either being HIV negative and/or using no 
medication or having significant medical history. In a recent review, immunologically healthy 
individuals are referred to those with no apparent case of immunosuppression and include the 
elderly, patients with chronic liver or kidney disease, and those with idiopathic or transient 
lymphocytopenia (Fig. 8) (256). This description therefore lumps individuals with causes of 
possible immune dysregulation as being immunologically healthy. This begs the question who is 
immunologically healthy? 
 
This misinterpretation of immunologically healthy individuals becomes apparent when cases of 
PML are described in individuals that have a predisposing factor, such as older age, diabetes, 
and chronic infections, that may lead to immune dysregulation. Therefore, it is accurate to 
believe that all individuals presenting with PML are predisposed by some form of immune 
dysregulation. One such report, “Progressive Multifocal Leukoencephalopathy in a HIV 
Negative, Immunocompetent Patient,” (172) describes a 66-year-old male, with an undetectable 
JCPyV viral load in the CSF and a CD4+ >200, whom the authors define as being 
immunocompetent. However, upon further details it is noted that the patient had a history of 
HCV related cirrhosis and hepatocellular carcinoma. In another report, “Progressive Multifocal 
Leukoencephalopathy in an Immunocompetent Patient,” Aasly et al. describes a 72-year-old 
previously healthy woman who developed PML. The woman had a history of well-regulated 
hypertension and total alopecia at age 40 years with spontaneous improvements (110). There 
have been descriptions demonstrating associations between hypertension, proinflammatory 
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cytokines, and cells of the innate and adaptive immune systems (219). A series of cases by 
Gheuens et al. demonstrated that a certain degree of mild immunosuppression was present in 
38 PML cases who were HIV-negative and free of malignancies (82). The associated conditions 
among these individuals included hepatic cirrhosis, chronic renal failure, dermatomyositis, 
pregnancy, and Alzheimer’s disease.  
 
Therefore, these case reports may not be the prototypical definition of immunosuppression 
usually associated with PML, but prove the point that immune dysregulation may warrant an 
environment conducive for JCPyV related PML. The underlying mechanism of JCPyV 
reactivation resulting in PML in an array of individuals makes it difficult to find one cohesive 
cause for PML pathogenesis. It may not be one mechanism of reactivation leading to PML but 
multiple roads diverging.   
 
PML diagnosis and treatment  
The diagnosis of PML can be thought of as a three-stage process that includes clinical 
suspicion, radiological identification, and confirmation by cerebrospinal fluid or tissue analysis 
(44). Clinical suspicion relies on the character and development of focal neurological symptoms 
and signs over time and disease susceptibility. Once PML is suspected, brain lesions are 
detected and characterized via MRI. In the case of PML, characteristic white-matter lesions in 
the brain areas associated with the clinical deficits can be visualized. Demyelinating lesions are 
usually hyperintense on T2-weighted and FLAIR MRI sequences, but hypointense on T1-
weighted sequences, which indicate white matter destruction (Fig.10). Hypointense lesions help 
distinguish PML from other pathologies, primarily HIV-1 encephalopathy, which is characterized 
by diffuse central white-matter changes that are not detected on T1-weighted sequences.   
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Lastly, the laboratory methods used for a definitive PML diagnosis include detection of JCPyV 
DNA or proteins via in situ hybridization or immunohistochemistry on brain biopsy samples or by 
the detection of JCPyV DNA in CSF by PCR. Among patients with HIV-1 and neurological 
diseases not treated with HAART, the diagnostic sensitivity for PML with this technique was 72-
92%, with a specificity of 92-100% (45). However, in recent times, it has been more common to 
see negative JCPyV PCR results in AIDS patients that have clinical and imaging presentations 
making these patients indistinguishable from those patients with PML. The decreased viral 
replication and clearance of JCPyV DNA from the CSF is thought to be associated with the 
immune restoration process as a result of antiretroviral therapy (41). As a result of this, the 
sensitivity of PCR testing for JCPyV DNA has dropped to 58% (8). Histologically, PML is 
characterized by a productive and lytic infection of both oligodendrocytes and astrocytes that 
lead to multiple areas of demyelination in the CNS. There may also be reactive gliosis and giant, 
bizarre astrocytes in affected areas (230). Currently, there are no specific antiviral drugs against 
JCPyV. Without a specific antiviral drug, the current treatment goal in PML is to restore the host-
adaptive immune response to JCPyV for control of the infection. In HIV-positive patients, this 
goal is accomplished mainly by treatment of HAART. In HIV-negative patients, the main 
therapeutic objective is to reduce, if possible, immunosuppressive drugs, enabling the adaptive 
immune system to control the infection. However, in organ transplant recipients, decreasing 
these drugs increases the risk of graft rejection. Therefore, a better strategy might be to 
augment the cellular immune repose to JCPyV by use of immunotherapies such as dendritic cell 
vaccines (230).  
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Figure 10. Cerebellar lesions in a patient with PML via MRI:  An MRI scan of a lymphocytic 
leukaemia patient with classic PML. The patient was identified as JCPyV positive via PCR 
detection of JCPyV in the CSF. Lesions (arrows) were identified by fluid attenuated inversion 
recovery (FLAIR) (Fig 4A and 4C) and T1-weighted MRI (Fig 4B and 4D) (230).  
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PML-immune reconstitution inflammatory syndrome (IRIS) 
IRIS is an inflammatory syndrome in response to clinically apparent or subclinical pathogens 
associated with the recovery of the immune system after a period of immunosuppression 
(Fig.11). In certain cases, a rapid global recovery of the immune system may not be favorable. 
So although a cellular immune response directed against JCPyV is beneficial in classic PML, 
PML-IRIS can be triggered if such a recovery of the immune system were to occur. HIV-1 
associated PML-IRIS comprises of three elements. First, immune reconstitution, meaning a 
decrease of plasma HIV-1 RNA with or without an increase in CD4+ T cells associated with the 
start of combined antiretroviral therapy. Second, tissue inflammation, and third, clinical disease 
or worsening that would not be expected from the natural course of the disease (77, 215). IRIS 
may occur during either of the two phases of immune restitution that occurs after the initiation of 
HAART (197). The first period of susceptibility occurs in the initial weeks when the increase in 
CD4+ T cells is largely due to the redistribution of pre-existing memory T cells. The late phase is 
a direct result of the proliferation of naïve T cells, usually after 4-6 weeks but can be as long as 
4 years after the initiation of HAART (103). In PML, IRIS occurs in two settings, the first known 
as paradoxical IRIS, where inflammation develops in relation to existing lesions as a result of 
the symptomatic disease being treated with combined antiretroviral therapy. The second setting, 
known as unmasking IRIS, happens when patients develop PML after the start of combined 
antiretroviral therapy and an inflammatory picture is found via MRI (76).  
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Figure 11. PML induced immune reconstitution inflammatory syndrome (IRIS): 
Unregulated or prolonged immunosuppression can lead to poor clinical prognosis of PML. As 
the immune response increases, for example by weaning a patient off of immunosuppressive 
drugs or starting HAART, prognosis improves as JCPyV is controlled (x-axis to the right). At 
some point prognosis once again declines as pathological IRIS develops. Inset depicts marked 
CD3 infiltration into the brain of a patient with IRIS that would not be found in a severely 
immunocompromised individual developing PML. Increases in inflammation breaks down the 
blood-brain barrier during immune reconstitution. However, clinical intervention with 
corticosteroids can shift the inflammatory response to the left (47).  
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JCPyV animal models 
Many studies have established the oncogenic potential of JCPyV in laboratory animals but 
demonstrating infection, pathogenesis, and PML has remained elusive. The major challenge in 
creating an animal model for JCPyV infection and disease is the inability of JCPyV to replicate 
in nonhuman cells. It has been demonstrated that in owl monkeys (Aotus trivirgatus) and 
squirrel monkey (Saimiri sciureus), JCPyV infection does not progress past the early phase of 
infection where only TAg is expressed with a lack in expression of capsid proteins and no viral 
DNA replication (251). Inoculation with JCPyV intracerebrally, subcutaneously, or intravenously 
in owl monkey and squirrel monkey models resulted in the development of astrocytoma, 
glioblastoma, and neuroblastoma (140, 141). Interestingly, juvenile owl monkeys inoculated 
intracerebrally with Mad-1 JCPyV remains the only report of infectious virus recovered from 
tissue or tumors of any experimental animal species inoculated with JCPyV (153).  Similar 
results were demonstrated in rodent models, for instance, when newborn golden Syrian 
hamsters (Mesocricetus auratus) were inoculated subcutaneously and intracerebrally with 
JCPyV multiple brain tumors resulted (243, 264). Recently, a novel mouse model engrafted with 
human lymphocytes and thymus, designated humanized NOD/SCID/IL-2-Rg (null) mice, has 
been described (226). Mice inoculated with JCPyV remained asymptomatic, however, JCPyV 
DNA was occasionally detected in the blood and urine of infected animals. Interestingly, mice 
generated both humoral and cellular immune responses in conjunction with the expression of 
the immune exhaustion marker, PD-1, consistent with response to infection (226).  Although 
humanized mice represent a novel animal model to study the interactions of JCPyV with the 
immune system, this model along with the previously described animal models does not 
embody a working model to study PML pathogenesis. A summary by Khalili et al. of previously 
studied JCPyV animal models are described in Table 2 (251).   
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Table 2. JCPyV animal models  
Species Agent Introduction Outcome NCCR References 
Owl monkey/ 
Squirrel 
monkey 
Purified 
JCPyV 
Intracerebral 
injection 
Astrocytoma Mad-1 London et al. (1978) 
(140); Houff et al. 
(1983) (101); London 
et al. (1983) (141)   
Owl monkey Purified 
JCPyV 
Intracerebral 
injection 
Astrocytoma Mad-1 Major et al. (1987) 
(153) 
Syrian golden 
hamster 
Purified 
JCPyV 
Intracerebral 
injection 
Glioma Mad-1 Walker et al. (1973) 
(243) 
Syrian golden 
hamster 
Purified 
JCPyV 
Intracerebral 
injection 
Medulloblastoma Mad-4 Zu Rhein and Varakis 
(1979) (264) 
Mice JCPyV TAg Transgenic Adrenal 
Neuroblastoma 
Mad-1 Small et al. (1986) 
(220) 
Mice JCPyV TAg Transgenic CNS 
Dysmyelination 
Mad-1 Small et al. (1986) 
(221); Trapp et al. 
(1988) (235); Hass et 
al. (1994) (91) 
Mice Polyoma 
TAg 
Transgenic CNS 
Dysmyelination 
Murine 
PyV 
Baron-van 
Evercooren et al. 
(1992) (9) 
Mice JCPyV TAg Transgenic Medulloblastoma/ 
PNET 
Archetype 
(CY) 
Krynska et al. (1999) 
(130) 
Mice JCPyV TAg Transgenic MPNST Mad-4 Shollar et al. (2004) 
(217) 
Engrafted 
NOD/SCID/IL-
2-Rg (null) 
mice 
Purified 
JCPyV 
Intraperitone
al injection 
Anti-JCPyV 
immune 
response 
Mad-4 or 
CY 
Tan et al. (2013) 
(226) 
SHIV infected 
Rhesus 
monkeys 
SV40 Intravenous 
injection 
Meningo-
encephalitis and 
demyelination 
SV40 Axthelm et al. (2004) 
(7) 
Nude mice JCV-
infected 
human 
cells 
Intracerebral 
injection 
Persistence of 
infected cells 
Mad-1 Matoba et al. (2008) 
(160) 
Engrafted 
Rag2-/- 
Mbpshi/Shi mice 
Purified 
JCPyV 
Intracerebral 
injection 
Demyelination  Mad-1 Kondo et al. (2014) 
(126) 
(251) T Antigen (TAg), Primitive neuroectoddermal tumor (PNET), Malignant peripheral nerve 
sheath tumor (MPNST)  
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Background for research question  
Understanding the mechanisms underlying the development of PML has been hampered by the 
inability to conclusively delineate the sites of JCPyV latency and reactivation in humans, the 
inability to demonstrate rearrangement of archetype JCPyV in an in vitro replication model, and 
the absence of an in vivo animal model to study JCPyV pathogenesis. To date, no experimental 
studies have been conducted to demonstrate the infection of urine-derived archetype JCPyV in 
primary renal proximal tubule epithelial (RPTE) cells, the reactivation and/or rearrangement of 
archetype JCPyV, and the infection of archetype JCPyV in an in vivo animal model. Thus, there 
is a gap in our understanding of the primary sites of initial infection, the events responsible for 
the reactivation and rearrangement of archetype JCPyV into the pathogenic rearranged form 
that causes PML, and a suitable animal model to study the pathogenesis of JCPyV.  
 
Long-Term Goal, Objective, and Hypothesis 
Our long-term goal is to delineate the natural history of archetype JCPyV infection, 
reactivation, and rearrangement for evidence-based approaches to improve treatment for PML. 
The objective of this study is to understand the cellular and molecular events leading to JCPyV 
infection, rearrangement, and/or reactivation. The aims of the proposed research are to 
determine the tropism of urine-derived archetype JCPyV in primary RPTE cells, to delineate the 
importance of genomic alterations in the pathogenesis of PML, to establish an in vitro model of 
JCPyV rearrangement, and to establish an in vivo JCPyV animal model. We hypothesize that i) 
urine-derived archetype JCPyV will be able to infect RPTE cells, ii) the presence of TAg will 
induce JCPyV NCCR rearrangements in an in vitro system, iii) alterations to the viral capsid will 
result in altered JCPyV replication kinetics and iv) archetype and rearranged JCPyV can infect 
NOD scid gamma (NSG) mice. 
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Specific Aims 
Specific Aim 1: Investigate archetype JCPyV rearrangement and cellular tropism using brain 
and kidney in vitro model system. 
Specific Aim 1a: Investigate archetype JCPyV infection and replication in primary RPTE 
cells. 
Specific Aim 1b: Demonstrate rearrangement of archetype JCPyV in a linear reinfection 
model using COS-7, RPTE, and primary human brain microvascular endothelial 
(HBMVE) cells. 
Specific Aim 1c: Determine the cellular tropism and replication kinetics of urine-derived 
rearranged archetype JCPyV replication using RPTE, HBMVE, human brain cortical 
astrocytes (HBCA) and primary human fetal glial (PHFG) cells as in vitro model systems. 
Hypothesis: We hypothesize that propagated urine-derived archetype JCPyV will infect primary 
RPTE cells. Furthermore, sequential reinfection and passaging of urine-derived archetype 
JCPyV in COS-7 cells constitutively expressing TAg and/or in primary cells will result in changes 
to the NCCR leading to altered cellular tropism.  
Approach: The susceptibility of primary RPTE cells to archetype JCPyV infection will be 
monitored by detection and analysis of JCPyV DNA, RNA, protein, and infectious virions. 
Quantitative analysis of JCPyV genome copies and RNA transcripts will be conducted using 
qPCR and qRT-PCR of JCPyV TAg and VP1 from days 1 to 20 after infection, as previously 
described (32). JCPyV TAg protein will be detected by immunoprecipitation/ western blot 
(IP/WB) and JCPyV VP1 protein by immunofluorescence assay (IFA) from archetype JCPyV-
infected primary RPTE cells at 10 and 15 days after infection (35). Confirmation of the presence 
of viral particles will be demonstrated via transmission electron microscopy (TEM). NCCR 
sequence analysis will be conducted at days 0, 5, 10, 15, 20, 25, 30 and 35, of archetype 
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JCPyV-derived from infected RPTE cells. To demonstrate the production of infectious archetype 
JCPyV virions, naïve RPTE cells will be infected with virus isolated from previously infected 
RPTE cells collected at day 35 after infection. After archetype JCPyV infection of COS-7 cells, 
cells will be passaged every 10 days and one half of the infected cells will be kept for 
continuous growth, and remaining cells will be used for DNA extraction. After archetype JCPyV 
infection of primary RPTE and HBMVE cells, a portion of infected cells will be used for DNA 
extraction, with the remainder of the cells will be lysed and used to reinfect naïve cells. 
Rearrangement of archetype JCPyV will be monitored every 10 days by NCCR PCR and 
sequence analysis.  
 
Specific Aim 2: Investigate the role of JCPyV VP1 alterations in viral replication and JCPyV 
pathogenesis 
Specific Aim 2a: Determine if archetype JCPyV +/- VP1 mutations alter viral DNA 
replication, infectious virus production, and non-coding control region (NCCR) 
rearrangement following transfection into HBMVE cells. 
Specific Aim 2b: Demonstrate that replication activity of transfected JCPyV archetype 
plasmids is comparable to infection in HBMVE cells.  
Hypothesis: We hypothesize that VP1 alterations in JCPyV will result in an increase in virus 
replication, an increase in virus production, and NCCR rearrangement following transfection into 
HBMVE cells. 
Approach: Primary HBMVE cells will be transfected with 25 ng of either parental constructs of 
archetype JCPyV (CY), rearranged JCPyV (Mad1 or M1), or hybrid JCPyV (CYrM1c), which 
contains an archetype NCCR in the backbone of rearranged JCPyV (Mad1) coding region. 
HBMVE cells will also be transfected with 25 ng of either CYrM1c constructs with the VP1 
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mutations CYrM1c-S267F or CYrM1c-L55F. Cells will be harvested at 4 hours and at days 3, 5, 
10 and 15 after transfection, and DNA and RNA will be extracted to analyze viral replication 
kinetics using qPCR and qRT-PCR for JCPyV early and late genes, TAg and VP1, respectively. 
In addition, primary human fetal glial (PHFG) cells will be transfected with 25 ng of M1, M1-
L55F, or M1-S267F, amplified via VP1 PCR, and sequenced. Lysate from PHFG transfected 
either with M1, M1-L55F, or M1-S267F will be sonicated, titered, and used to reinfect PHFG 
cells to demonstrate production of infectious virions. Lastly, COS-7 cells will be transfected with 
25 ng of CY to propagate infectious virus used to infect HBMVE cells. VP1 and NCCR 
sequence analysis will be conducted after each experiment. 
 
Specific Aim 3: Determine the susceptibility of humanized NSG mice to archetype and 
rearranged JCPyV infection. 
Hypothesis: Based on published literature showing human specific pathogen infection in 
humanized NSG mice (85, 209, 226) and JCPyV infection in human B cells (31, 166, 247), we 
hypothesize that JCPyV can infect humanized NSG mice. 
Approach: Prior to infection, human immune cells engrafted in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ 
(NSG) mice will be confirmed by flow cytometry analysis. NSG mice will then be infected with 
either archetype JCPyV or Mad-1 rearranged JCPyV by intravenous injection. Blood and urine 
will be collected at 3, 5, 7, 14, 21, and 28 days after infection. JCPyV viral DNA and TAg protein 
in NSG mice will be detected by quantitative PCR (qPCR) and flow cytometry. 
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Significance 
Even with the advent of HAART, the incidence of PML has not changed. PML remains one of 
the important causes of mortality and morbidity among HIV/AIDS patients, with approximately 
4% of AIDS-related patients developing PML. In addition, the incidence of PML in HIV-
uninfected individuals has increased with the broader use of immunosuppressive and 
immunomodulatory drugs used to treat an array of systemic and neurologic autoimmune 
disorders. These agents include, but are not limited to, chemotherapies, rheumatologic disease-
modifying therapies, and multiple sclerosis (MS) treatments, which result in a decrease in 
immune surveillance of the CNS and therefore increased risk of PML in JCPyV infected 
individuals. Therefore, the lack of an archetype JCPyV replication, reactivation, and 
rearrangement model has hindered the understanding of mechanisms underlying the 
development of JCPyV pathogenesis and progression to PML. Unfortunately, there are no 
preventive or therapeutic options available to manage PML patients. Thus, the proposed study 
is significant in that it will utilize primary cells to meticulously delineate steps involved in primary 
archetype JCPyV pathogenesis and the understanding of such mechanisms may assist in 
developing preventative or therapeutic interventions for this incurable disease.  
 
PML is a subacute demyelinating disease of the CNS caused by the ubiquitous polyomavirus 
JC (JCPyV) (80, 195). The onset of PML is insidious, first presenting with neuropsychological 
deficits. The natural disease progression is usually rapid, with death ensuing in 3 to 6 months 
after diagnosis. The neuropathological hallmarks of PML consist of multifocal microscopic and 
macroscopic demyelinating lesions typically in the subcortical white matter near the gray-white 
matter junction. Ultrastructural examination reveals nuclei of infected oligodendrocytes packed 
with electron-dense JCPyV particles, measuring approximately 40 nm in diameter (196). PML 
was originally recognized as a rare complication of hematological malignancies or systemic 
55 
 
inflammatory disorders, however, a dramatic 50-fold increase in the incidence in the last thirty 
years occurred as a result of the HIV/AIDS epidemic (12). AIDS is the most frequent condition 
associated with PML (132), with approximately 6% of patients developing AIDS related PML (3, 
164). Moreover, a recent report on 151 brain pathology confirmed that in the post-HAART era 
cases of PML remained unchanged (132). A resurgence of PML occurred in the 2000s as a 
result of the use of immunomodulatory compounds like the monoclonal antibodies natalizumab, 
efalizumab, and rituximab for the treatment of the autoimmune conditions such as, multiple 
sclerosis, Crohn’s disease, severe forms of plaque psoriasis, hematologic malignancies, and 
rheumatoid arthritis (148).  
 
JCPyV, a member of the genus, Orthopolyomavirus, has a naked icosahedral capsid and a 
circular double-stranded DNA genome of about 5.1 kb (118, 146). The viral genome is 
functionally divided into an early region (2.4 kb) encoding large and small T proteins along with 
the recently described T’ proteins generated by alternative splicing of the early mRNA; a late 
region (2.3 kb) encoding viral capsid proteins VP1, VP2 and VP3, the accessory agnoprotein; 
and a non-coding regulatory region (0.4 kb) encompassing the noncoding control region 
(NCCR). Based upon the structure of the NCCR, two types of JCPyV have been identified: the 
archetypal form, which is predominantly detected in kidney and urine and the rearranged form 
which is predominantly detected in brain, tonsil and lymphocytes (81, 213). Archetype JCPyV is 
detected in the urine of people with and without PML, and its NCCR consists of 6 regions 
designated A-F. Conversely, the regulator region of JCPyV isolated from PML patients display 
rearrangements, with deletions, duplications, tandem repeats, and insertions. It is thought that 
all other rearranged forms of JCPyV arise from the archetype form, and most likely arise during 
immunosuppression. Serological data indicate that JCPyV infection usually occurs during 
childhood and is typically subclinical (182). Asymptomatic JCPyV infection occurs in 60 to 80% 
of healthy individuals. The route of JCPyV transmission and the primary sites of replication are 
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unknown, although, viruria is common, and transmission via urine to oral/respiratory route and 
primary replication in tonsillar tissue has been proposed (166, 168, 213, 241). Virus-infected 
lymphocytes or cell-free virus presumably spread by the hematogenous route from the primary 
site to secondary sites, such as kidneys, lymphoid tissues and brain, to establish focal areas of 
infection or persistence (56, 166, 168, 176, 233, 249). PCR analyses have suggested that 
JCPyV may persist in brain, tonsils and lymphocytes of individuals with and without PML (56, 
168, 175, 176, 233, 249), and PML might arise from reactivation of JCPyV.  
 
The host cell range of archetype JCPyV is strictly restricted in cultured cells, where researchers 
have demonstrated poor to moderate replication of archetype JCPyV in transformed cell lines, 
such as PHFG cells transformed with an origin-defective mutant of simian virus 40 (SV40) 
(POJ-19) and simian kidney cells transformed with an origin-defective mutant of SV40 (COS-7) 
cells, respectively (50, 95). In vitro data indicates that various archetype JCPyV DNA clones can 
initiate efficient virus replication with the conservation of the NCCR after transfection in COS-7 
cells (95). In contrast, it has been demonstrated that rearranged Mad-1 JCPyV can efficiently 
replicate in primary cells, including PHFG and HBMVE cells (35). Therefore, it has yet to be 
determined if archetype JCPyV can infect and replicate in primary RPTE cells.  
 
Cell type specificity of JCPyV within human cells occurs at the transcriptional level. Regulation 
of transcription is dependent on the sequence of the NCCR, as well as the availability of host 
transcription factors, which are the determining factor in both the start sites of early 
transcription, as well as the quantity of T antigen produced (70). Unlike other human DNA 
viruses, such as herpesviruses, JCPyV does not bring transcriptional activating proteins into 
newly infected cells. Although host cell factors are the determining factor in directing early 
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transcription, the exact profile of transcription factors involved in reactivation and rearrangement 
remain elusive. 
Interestingly, in vivo studies have confirmed the oncogenic potential of JCPyV but due to 
JCPyV’s strict host tropism, demonstrating infection, pathogenesis, and PML in animals has 
been limited. Recently, a novel mouse model engrafted with human lymphocytes, designated 
humanized NOD/SCID/IL-2-Rg (null) mice has been described (226). However, infection using 
urine-derived archetype JCPyV in this model system has yet to be described.   
 
Innovation 
Previous studies have either used a transfection based JCPyV method or utilized transformed 
cell lines to try to address questions regarding JCPyV replication. The proposed research 
utilizes in vitro primary HBMVE and RPTE cells, which have never been described in archetype 
JCPyV infection. This study aims to identify the differences in the host cell tropism of archetype 
JCPyV, to establish an in vitro model to study genomic alterations of archetype JCPyV, and 
develop an in vivo animal model to study JCPyV infection. Furthermore, for the first time, we 
have demonstrated in vitro rearrangement of archetype JCPyV. Utilizing this rearranged strain 
of JCPyV we will be able to delineate the events that have led to this rearrangement by 
addressing the transcription factor profile and cellular tropism. By utilizing these primary cells, 
future studies will be done to identify transcription factors involved in the reactivation and 
rearrangement of urine-derived archetype JCPyV. This study will lay the foundation to further 
understand how host cell tropism and transcription factors play a role in the latency, productive 
infection, reactivation, and rearrangement of JCPyV, which will impact the development of 
much-needed therapeutic interventions for PML.  
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Abstract 
Background: The human polyomavirus JC (JCPyV) is the causative agent of the fatal 
demyelinating disease progressive multifocal leukoencephalopathy (PML). While the archetypal 
form of the virus is ubiquitous in the healthy human population, it is the rearranged form that is 
responsible for PML. The archetype form of JCPyV has a conserved noncoding control region 
(NCCR) that is defined by six designated blocks, A-F. However, the rearranged form has 
deletions and/or duplications in its NCCR. Although it has been established that the rearranged 
form of JCPyV is pathogenic, the events leading to the reactivation and/or rearrangement in its 
NCCR have yet to be determined. Thus, the lack of an archetype JCPyV replication model has 
hindered the understanding of mechanisms underlying the development of PML pathogenesis. 
Methods: JCPyV isolated from urine was purified using sucrose gradient. JCPyV replication 
kinetics conducted in primary renal proximal tubule epithelial (RPTE), human brain 
microvascular endothelial (HBMVE), human brain cortical astrocytes (HBCA) and primary 
human fetal glial (PHFG) cells was characterized using quantitative PCR (qPCR), reverse 
transcriptase-PCR (qRT-PCR), hemagglutination assay (HA), immunofluorescence assay (IFA), 
immunoprecipitation (IP)/western blot (WB) and transmission electron microscopy (TEM). COS-
7, HBMVE, and RPTE cells were infected with urine-derived archetype JCV and passaged 
every 10 days. Cell lysates were collected for DNA and RNA analysis and for reinfection. 
Characterization of the novel rearranged virus isolated from infected COS-7 cells at day 645 
was performed by infecting HBMVE, HBCA, and RPTE cells. Following infection, DNA and RNA 
was collected at designated time points over the course of 35 days, whereby the replication 
kinetics were observed by qPCR and qRT-PCR. Lastly, predictive bioinformatics analysis 
determined transcription factor binding motifs present in urine-derived archetype JCPyV and 
D645 rearranged JCPyV as compared to CY and Mad-1 variant.  
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Results: JCPyV TAg protein was detected in RPTE and HBMVE cells by IP/WB and JCPyV VP1 
protein by IFA. Viral particles within the nucleus of RPTE and HBMVE cells were detected by 
TEM. Re-infection of naïve RPTE and HBMVE cells with lysates from archetype infected RPTE 
and HBMVE cells demonstrated an exponential increase of DNA and RNA 15 days after 
infection. Sequence analysis of infected HBMVE, RPTE, HBCA, and PHFG cells demonstrated 
no alterations in the genome of archetype JCPyV. Interestingly, rearrangement of urine-derived 
archetype JCPyV NCCR occurred in vitro at 645 days after infection in COS-7 cells. At 645 days 
after infection in COS-7 cells, one base pair substitution in block A, one base pair substitution in 
block B, an 8 base pair insertion in block C, and 5 base pair deletion in block F were observed 
in the NCCR, with no changes to VP1. Characterization of the replication kinetics of day 645 
rearranged virus demonstrated limited replication in HBMVE and RPTE cells, and non-
productive replication in HBCA cells. Predictive bioinformatic analysis reveals distinct 
transcription factor binding sites that may give insight into differences in JCPyV replication. 
Conclusions: These data demonstrate infection and efficient replication of archetype JCPyV in 
RPTE and HBMVE cells, and limited or no replication in HBCA and PHFG cells. To our 
knowledge, this is the first time demonstrating the ability for urine-derived archetype JCPyV to 
rearrange in vitro and to be infectious in naïve primary cells. By identifying the differences in the 
cellular tropism of urine-derived archetype JCPyV, D645 rearranged JCPyV, CY, and Mad-1 
variants and profiling transcription factors important in the replication, rearrangement, and/or 
reactivation of these variants, this study will therefore give insight on cellular conditions involved 
in urine-derived archetype JCPyV pathogenesis. 
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Introduction   
The human polyomavirus JC (JCPyV) belongs to the Polyomaviridae family and has a naked 
icosahedral capsid with a circular double-stranded DNA genome that is approximately 5.1-kb in 
length and consists of three different regions: the noncoding control region (NCCR), the early 
coding region, and the late coding region. The early transcriptional unit encodes the small and 
large T antigens, whereas the late transcriptional unit encodes the agnoprotein and the viral 
structural proteins VP1, 2, and 3.  
 
Based upon the structure of the NCCR, two types of JCPyV have been identified in humans, the 
archetypal form and the rearranged form. Archetype JCPyV is found in the urine of healthy 
people, as well as those affected with PML (260) and is the form that is thought to circulate in 
the human population. Minor sequence variation exists in the genomes of independent isolates 
of archetype JCPyV (259, 260). The rearranged form of JCPyV has deletions and/or 
duplications in the NCCR sequence and is thought to evolve from archetype JCPyV (260). First 
isolated in 1971, the rearranged form of JCPyV has been associated with PML (183). PML is 
the only known human viral demyelinating disorder and is characterized by multiple foci of 
demyelination caused by the lytic infection of oligodendrocytes by JCPyV. Once considered to 
be rare, a resurgence of PML in the last 30 years has been attributed to HIV/AIDS and more 
recently to the use of monoclonal antibodies to treat multiple sclerosis and autoimmune 
conditions (28). Although it has been suggested that the rearrangement of the NCCR is critical 
in the development of PML among immunocompromised patients, the exact mechanism of 
NCCR rearrangement has not been clearly defined (150). It has been suggested that the 
rearranged form may be generated during virus replication, yielding a new, potentially more 
active form of the virus (49). The regulatory region of JCPyV isolated from the CSF and brain of 
PML patients shows rearrangements, including duplications, tandem repeats, insertions and 
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deletions. The rearranged form has been reported in the tonsils and lymphocytes of people with 
and without PML (213). However, NCCR rearrangement of archetype JCPyV has yet to be 
demonstrated in vitro. 
 
Using various molecular techniques, archetype JCPyV has been detected in various human 
organs and tissues, including kidney (39, 123), gastrointestinal tract (193, 211), tonsil (88, 112) 
and bone marrow (159). However, the exact site(s) of archetype JCPyV infection and replication 
and the cell types that harbor latent archetype JCPyV remain poorly understood. Although 
detection of JCPyV has been demonstrated in the kidneys (39, 123), to our knowledge, there 
have been no studies demonstrating the infection of urine-derived archetype JCPyV and its 
replication and/or production of infectious virions in kidney cells. Furthermore, we previously 
demonstrated productive in vitro infection of primary human brain microvascular endothelial 
(HBMVE) cells by rearranged  JCPyV (Mad-1A) (35). However, whether archetype JCPyV can 
infect and replicate in primary renal proximal tubule epithelial (RPTE) cells, HBMVE cells, and 
human brain cortical astrocytes (HBCA) has yet to be determined. In this study we conclusively 
demonstrate that archetype JCPyV can be propagated, that archetype JCPyV can infect and 
efficiently replicate in primary RPTE and HBMVE cells, while abortive replication occurs in 
HBCA cells and nonproductive infection occurs in primary human fetal glial (PHFG) cells, and 
rearrangement of urine-derived archetype JCPyV occurs in vitro in COS-7 cells at 645 days 
after infection. 
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Results  
Isolation of archetype JCPyV from urine 
Urine samples from 17 healthy volunteers were screened for the presence of JCPyV 
(Supplemental Fig. 1A) by qPCR of JCPyV TAg. Of the 17 volunteers, 13 had detectible JCPyV 
TAg genome copies, while four volunteers tested negative. JCPyV NCCR sequence analysis 
was conducted for samples that tested qPCR positive for JCPyV TAg. NCCR sequences of 
urine-derived JCPyV from five volunteers were compared with archetype and rearranged JCPyV 
sequences from Genbank (Supplemental Fig. 1B). In this study, we have screened, isolated, 
and confirmed via sequence analysis that a proportion of healthy volunteers excrete archetype 
JCPyV in their urine (Supplemental Fig. 1 and Supplemental Table 1).  
 
Propagation of archetype JCPyV in COS-7 cells 
COS-7 cells were infected with rearranged JCPyV to ensure their susceptibility to JCPyV 
infection. Semi-confluent COS-7 cells, grown in 35 mm plates, were inoculated with 0.5, 1 (data 
not shown), or 5 HA units of rearranged JCPyV and replication kinetics was measured by qPCR 
and qRT-PCR to determine the optimal infecting dose. COS-7 cells were then innoculated with 
archetype JCPyV isolated from urine to assess whether archetype JCPyV can be propagated 
using COS-7 cells as previously suggested (94). COS-7 cells were innoculated with 41 HA of 
urine-derived archetype JCPyV isolated from patient 7 (Supplemental Fig. 1A) and JCPyV 
replication was monitored by qPCR and qRT-PCR. JCPyV TAg and VP1 viral DNA and RNA 
transcripts were detected as early as 24 hr and 5 days after infection, respectively, increasing 
exponentially in parallel (Fig. 1A). The total JCPyV TAg (4.7 x 1011) and VP1 (7.3 x 1011) 
genome copies recovered from each 35 mm plate 25 days after infection were approximately 
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373- and 3.7 x 103-fold higher than the mean genome copies used to infect (infecting dose, ID), 
suggesting efficient replication of archetype JCPyV in COS-7 cells.  
 
To further test the specificity of JCPyV TAg specific primers, we employed JCPyV and SV40 
TAg specific primers and probes to amplify COS-7 cells infected with JCPyV. We demonstrate 
that JCPyV TAg specific primers and probe are specific to JCPyV with no cross reaction to 
SV40 TAg. As indicated in (Supplemental Fig. 2A), both control and JCPyV infected samples 
demonstrate a basal expression of SV40 TAg as compared to the house-keeping gene GAPDH 
in COS7 cells. This is in contrast to JCPyV (Supplemental Fig. 2B) where we see a steady 
increase of JCPyV TAg cDNA/mRNA over the course of 25 days when compared to GAPDH.  
 
HA of combined cell lysate and supernatant collected at day 35 after infection confirmed the 
presence of archetype JCPyV virions in COS-7 cells. Due to the anticipation of a lower 
concentration of archetype JCPyV virions in infected COS-7 cells, a lower starting dilution for 
the HA was used, where we demonstrate approximately 21 HAU archetype JCPyV per µL. The 
replication kinetics and HA of rearranged JCPyV-infected COS-7 cells was also assessed (Fig. 
1B). Due to the anticipation of a higher concentration of rearranged JCPyV virions in infected 
COS-7 cells, a higher dilution for the HA was used, where we demonstrate approximately 51 
HAU of rearranged JCPyV per µL. These results demonstrate the potential to amplify infectious 
archetype JCPyV virions in COS-7 cells. Archetype JCPyV propagated and purified utilizing this 
method was used to conduct all pathogenesis studies described in this report using various 
susceptible cells.  
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Archetype JCPyV infection in primary HBMVE and RPTE cells 
In at least three independent experiments, we examined the susceptibility of primary HBMVE 
and RPTE cells to archetype JCPyV infection and monitored the replication kinetics from days 1 
to 20 after infection. Quantitative analysis of JCPyV TAg and VP1 genome copies and RNA 
transcripts was conducted by qPCR and qRT-PCR. Viral DNA was detected as early as 24 hr 
after infection, while RNA transcripts were detected as early as 5 days after infection in both 
HBMVE and RPTE cells. DNA and RNA transcripts increased exponentially after infection, 
where at day 20 the total JCPyV TAg (4.1 x 109) and VP1 (9.5 x 108) genome copies recovered 
from each 35 mm plate seeded with HBMVE cells were approximately 1.9 x 103- and 8.6 x 102-
fold higher than the mean genome copies used for infection (Fig. 2A). In RPTE cells, the total 
JCPyV TAg (1.0 x 1012) and VP1 (2.7 x 1010) genome copies recovered were approximately 2.5 
x 103- and 1.3 x 102 fold higher than the mean genome copies used for infection (Fig. 3A). 
Furthermore, JCPyV TAg protein was detected by IP/WB from archetype JCPyV-infected 
primary HBMVE (Fig. 2B) and RPTE (Fig. 3B) cells harvested 15 days after infection. At day 15, 
approximately 8% of primary HBMVE (Fig. 2C) and 6% of RPTE (Fig. 3C) cells expressed 
JCPyV VP1 protein using IFA. TEM confirmed the presence of viral particles with a diameter of 
40 - 45 nm within the nucleus of HBMVE (Fig. 2D) and RPTE (Fig. 3D) infected cells. NCCR 
sequence analysis was conducted on archetype JCPyV infected HBMVE and RPTE cells, with 
no change in NCCR sequence when compared to DNA extracted from input archetype JCPyV 
used to infect and DNA extracted from any time point thereafter (Supplemental Fig. 2). To 
demonstrate the production of infectious archetype JCPyV virions, naïve HBVME and RPTE 
cells were infected with virus isolated from previously infected HBVME and RPTE cells collected 
at day 35 after infection (Fig. 4A and 4B). DNA replication and RNA transcripts in naïve cells 
were comparable to those observed in archetype JCPyV infected HBMVE and RPTE cells (Fig 
1A and 2A).  
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Archetype JCPyV infection in primary HBCA and PHFG cells 
Next we examined the susceptibility of primary HBCA to archetype JCPyV and compared its 
replication kinetics with that of rearranged JCPyV (Mad-1). JCPyV TAg and VP1 DNA copies 
and RNA transcripts (Fig. 5A) were detected in HBCA as early as 5 days after infection with 
archetype JCPyV, however, the genome copies and viral transcripts plateaued at day 10 after 
infection. At day 20 after archetype JCPyV infection, the total JCPyV TAg (3.1 x 108) and VP1 
(3.6 x 107) genome copies recovered from each 35 mm plate of HBCA were approximately 27- 
and 33- fold higher than the mean genome copies used for infection. In contrast, rearranged 
JCPyV showed a steady increase of both DNA and RNA over the course of 20 days. At day 20 
after Mad-1 JCPyV infection, the total JCPyV TAg (2.4 x 1010) and VP1 (4.1 x 1010) genome 
copies recovered from each 35 mm plate of HBCA were approximately 58- and 2.5 x 102- fold 
higher than the mean genome copies used for infection (Fig. 5B). Interestingly, neither JCPyV 
TAg protein was detected by IP/WB from archetype JCPyV-infected primary HBCA cells 
harvested 15 days after infection (Fig. 5C) nor VP1 staining was detected using IFA (data not 
shown). However, IFA demonstrated that approximately 1% of primary HBCA cells expressed 
JCPyV TAg protein at 15 days after infection (Fig. 5D).  
 
On the basis that rearranged, but not archetype JCPyV infects PHFG cells (152), the 
susceptibility of PHFG cells to archetype JCPyV infection was examined. Archetype JCPyV TAg 
and VP1 genome copies were detected as early as day 1 after infection and declined slightly 
thereafter, while JCPyV TAg RNA transcripts were detected in PHFG cells as early as day 5 
and declined steadily thereafter (Fig. 6A). VP1 RNA transcripts were not detected. Moreover, 
JCPyV TAg protein was not detected by IP/WB from archetype JCPyV-infected PHFG cells 
harvested at 15 days after infection (Fig. 6C). In contrast, rearranged (Mad-1) JCPyV replicated 
efficiently in PHFG cells. At day 20 after Mad-1 JCPyV infection, the total JCPyV TAg (2.2 x 
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1011) and VP1 (5.3 x 1011) genome copies recovered from each 35 mm plate of PHFG cells 
were approximately 1.7 x 103- and 5.0 x 103-fold higher than the mean genome copies used for 
infection (Fig. 6B).  
 
In vitro rearrangement of urine-derived archetype JCPyV  
NCCR sequence analysis was conducted on day 35 infected HBMVE, RPTE, COS-7, and re-
infected naïve HBMVE and RPTE cells with JCPyV infected HBMVE and RPTE cell lysates, 
with no change in JCPyV NCCR sequences (Fig. 7). Interestingly, rearrangement of urine-
derived archetype JCPyV NCCR occurred in vitro at 645 days after initial infection in COS-7 
cells. This unique rearrangement resulted in one base pair substitution in block A, one base pair 
substitution in block B, an 8 base pair insertion in block C, and 5 base pair deletion in block F in 
the NCCR, with no changes to VP1. Sixteen binding sites present in CY, urine-derived 
archetype, and/or Mad-1 JCPyV were not present in D645 JCPyV as a result of its unique 
rearrangement (Table 1). As a result of the NCCR rearrangement of urine-derived archetype 
JCPyV altered replication kinetics were observed. Characterization of the replication kinetics of 
day 645 rearranged JCPyV (Fig. 8) demonstrated limited replication in HBMVE and RPTE cells, 
and non-productive replication in HBCA cells. 
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Discussion  
Although we know that the archetype form of JCPyV circulates in the healthy human population 
(125) and that the rearranged form of JCPyV causes PML, the definitive route of transmission 
and the site(s) of primary replication prior to reactivation have not been clearly defined (84). It is 
thought that JCPyV infected lymphocytes and/or cell-free virus disseminates via the 
hematogenous route from primary sties of infection to secondary sites to establish focal areas of 
virus persistence (233). JCPyV has been detected in different tissues and organs in the human 
body including the tonsils (168), kidney (227, 261), bone marrow (227), brain (227), spleen 
(227), and gastrointestinal tract (192), however, it is unclear what specific cell type(s) and 
organs are permissive to archetype JCPyV infection, reactivation and rearrangement (114). The 
difficulty in delineating the cell types susceptible to archetype JCPyV infection has been a result 
of its restricted host cell range in vitro (70, 94, 114, 181). To address issues with the limited host 
cell tropism that JCPyV displays, studies have either focused on, but not limited to, using 
transformed cell lines to drive the replication of JCPyV and/or by introducing JCPyV DNA in 
cells via a plasmid based system (94). In this report, we demonstrate that urine-derived 
archetype JCPyV productively infects primary RPTE and HBMVE cells, while replication in 
HBCA cells is restricted and nonproductive, whereas the virus does not replicate in PHFG cells.  
 
Propagation of urine-derived archetype JCPyV in COS-7 cells 
One of the main difficulties in studying the natural history of archetype JCPyV acquisition, 
infection, and dissemination is the ability to isolate and/or propagate enough urine-derived 
archetype JCPyV to conduct these studies. To overcome the cumbersome task of isolating and 
propagating virus, investigators have employed a transfection-based system. An advantage to 
using such a system is having complete control of the JCPyV DNA used for transfection. 
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However, infection of urine-derived virus gives an opportunity to investigate naturally occurring 
variants independent of forced introduction of DNA where initial binding of virions and entry are 
ignored. In this regard, the progression of infection, including binding to the cell surface, entry, 
replication, and production of infectious virions can be studied in its entirety to understand 
archetype JCPyV cellular tropism. It has been reported that COS-7 cells support the replication 
of both archetype and rearranged JCPyV (94). In vivo data suggests that heterogeneous 
populations of PML-type NCCRs are ultimately derived (74, 104, 239) from the archetypal form 
of JCPyV over a period of time. Here we demonstrate that the period of time to propagate urine-
derived archetype JCPyV in vitro, 35 days, is long enough for amplification of infectious virions 
with the archetype-like phenotype, but a period of time much shorter than that found in vitro to 
create variants. As demonstrated by other groups, the COS-7 cell is an effective in vitro model 
to propagate archetype JCPyV (94, 177). Utilizing this method, we were able to investigate the 
infection potential, replication kinetics, and cellular tropism of naturally occurring archetype 
JCPyV isolated from urine in different primary cells.  
 
Archetype JCPyV infects and replicates in primary RPTE and HBMVE cells  
JCPyV infection in human cell culture has been restricted to glial, astrocytic, neuroblastoma, 
Schwann, and B-cell lymphoma cells (114). Of these studies, only the rearranged form of 
JCPyV was used to demonstrate susceptibility to infection, while studies demonstrating 
archetype JCPyV susceptibility utilized a transfection-based approach and/or non-human 
derived cells. JCPyV variants with archetype NCCR have been detected in the urine of 
immunocompetent persons, as well as JCPyV DNA in kidneys of non-PML persons (261) 
suggesting that JCPyV establishes a low-level persistent infection in the kidneys of healthy 
persons. However, the exact cell type that archetype JCPyV infects within the kidney and its 
ability to replicate and produce infectious virions has not been established until now. A previous 
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study demonstrated the expression of JCPyV TAg protein in RPTE cells but did not demonstrate 
the presence of DNA, RNA, or JCPyV virions (152). Although transfection can address the 
contribution of intracellular components, like DNA-binding proteins, in JCPyV transcription and 
DNA replication, transfection bypasses the question of binding potential of JCPyV to host cell 
receptors involved in the entry of permissive cell types. It has been shown that both α-2,3- and 
α-2,6-sialic acid receptors are present on epithelial cells within the kidney (92, 258) and 
therefore should be susceptible to JCPyV binding and entry. Our data clearly demonstrate the 
ability of archetype JCPyV to productively infect, replicate, and produce infectious virions in 
RPTE cells. 
   
Interestingly, there has been no data demonstrating the productive infection of archetype JCPyV 
in brain cells in vitro to support data found in vivo in which archetype JCPyV can be found in 
brains of healthy persons (228). Before delineating the mechanism of archetype JCPyV 
reactivation and rearrangement it is important to study the replication potential of archetype 
JCPyV in primary cell types of importance to PML pathogenesis. JCPyV latency in the brain 
prior to severe immunosuppression has remained inconclusive and controversial. Recent data 
demonstrates the presence of archetype JCPyV DNA in the brains of healthy controls (11, 228). 
Although rearranged Mad-1 JCPyV has been shown to productively infect and replicate in 
primary HBMVE cells (35), to our knowledge, this is the first study demonstrating that archetype 
JCPyV can infect and efficiently replicate in primary HBMVE cells. Our data, based on the 
expression of JCPyV early and late DNA, mRNA, protein, as well as the presence of archetype 
JCPyV virions and presence of infectious virions collectively demonstrate the productive 
infection and replication of archetype JCPyV in primary HBMVE cells. It is possible that prior to 
reactivation and rearrangement, archetype JCPyV is able to infect HBMVE cells that line the 
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blood-brain barrier (BBB) in immunocompetent persons, suggesting HBMVE cells susceptibility 
to infection after initial dissemination in the periphery.  
 
In archetype JCPyV infected RPTE and HBMVE cells, the observation of higher late VP1 RNA 
transcripts could be a result of TAg protein mediated autoregulation similarly demonstrated in 
SV40 models in which late viral RNA was synthesized at a higher level than early RNA (198). It 
has been noted in SV40 models that an accumulation of TAg protein results in binding to the 
NCCR, thus repressing early transcription (106). 
 
Restricted replication of archetype JCPyV in primary HBCA cells 
In addition to the detection of JCPyV in the CSF or brain, histopathological identification of 
enlarged oligodendroglial nuclei, bizarre astrocytes, and demyelination can be used to further 
confirm diagnosis of PML. Although in vitro data demonstrate the susceptibility of astrocytes to 
rearranged JCPyV after transfection (69), astrocyte susceptibility to archetype JCPyV infection 
has not been demonstrated to date. It is known that the NCCR of rearranged JCPyV contains 
transcription factor binding sites due to its repeat structure (70) which is conducive to viral gene 
expression and its possible promiscuousness in infecting different primary cells and cell lines in 
vitro. Our findings demonstrate that primary HBCA cells infected with archetype JCPyV results 
in an abortive replication phenotype where the early TAg protein is produced without the VP1 
protein or virion production. Similarly, the mechanism of the abortive replication in 
nonpermissive cells after treatment with monoclonal antibodies has been suggested to arise 
from the expression of the main viral oncogenic protein TAg in concert with other host tumor-
inducing factors (13). The inability of archetype JCPyV to productively infect HBCA cells may be 
due to the structure of its NCCR and the lack of appropriate transcription factor binding sites 
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identified in rearranged JCPyV (157). In addition, the cellular transcription factor profile in HBCA 
cells might differ from cells that show productive infection of archetype JCPyV. However, the 
physiological constituents of the BBB make it feasible that astrocytes that surround and stabilize 
the capillary endothelial cells via their perivascular endfeet may be the next sequential cell to be 
infected after HBMVE cell infection due to its close proximity. It is therefore possible that 
archetype JCPyV can traverse the BBB before rearrangement and reactivation, and find 
residence in HBCA cells where non-productive replication may occur during primary infection. 
Data has suggested that viral propagation and amplification occurs in an astrocytic reservoir 
prior to oligodendrocytic infection in vivo (126). Thus, only upon immunosuppression can 
reactivation and rearrangement of JCPyV occur within HBCA cells resulting in efficient 
replication.  
 
Archetype JCPyV does not replicate in PHFG cells  
The replication profiles of archetype and rearranged JCPyV differ in PHFG cells, a 
heterogeneous population of glial cells. While rearranged JCPyV replicates efficiently in PHFG 
cells (32), archetype JCPyV fails to produce infectious virions (49). Consistent with previous 
findings, our data demonstrate that archetype JCPyV does not replicate in PHFG cells 
reiterating that archetype JCPyV is incapable of effective replication in glial cells and must 
rearrange its NCCR before being able to effectively replicate in glial cells (223). It is believed 
that the phenotype of the archetype JCPyV NCCR may be conducive to maintaining a persistent 
infection in non-glial cells, as we have demonstrated in RPTE and HBMVE cells, but once 
immunosuppression occurs changes to the NCCR could result in the ability of rearranged 
JCPyV to permissively infect oligodendrocytes (6).  
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Constant expression of TAg drives rearrangement of urine-derived archetype JCPyV in 
COS-7 cells  
To our knowledge, this is the first description of in vitro rearrangement of archetype JCPyV. 
Since it has been demonstrated that SV40 TAg has a greater DNA binding activity to the JCPyV 
NCCR, as well as being more efficient in directing replication than that of JCPyV’s own TAg (21, 
40, 143), we utilized COS-7 cells constitutively expressing SV40 TAg to propagate archetype 
JCPyV. A previous study showed no rearrangements to the NCCR of JCPyV after transfection 
or infection in COS-7 cells cultured for weeks (94), and herein we show that propagation of virus 
stocks for 35 days also results in no rearrangements. This discrepancy was attributed to the fact 
that the period of time these JCPyV transfected or infected COS-7 cells were cultured was 
much shorter than the persistence of archetype JCPyV in human hosts in vivo. Thus, to 
overcome this shortcoming we decided to conduct an ongoing infection in COS-7 cells with no 
designated end point, which resulted in rearrangement to archetype JCPyV at 645 days after 
infection. It is known that the replication kinetics of JCPyV is a slow process even in susceptible 
cells where TAg is already present, however, it becomes clear that once an accumulation of 
TAg occurs, JCPyV viral replication proceeds (94, 151). Although the exact mechanism of 
NCCR rearrangement has yet to be described, it has been postulated that viral-replication-
dependent recombination events might be responsible for the generation of deletions and/or 
duplication in the NCCR of archetype JCPyV (107).  
 
Although bioinformatics tools like PROMO are powerful, limitations in identifying all the possible 
transcription factors that can bind to JCPyV NCCRs are dependent on data incorporated into 
the PROMO database from previous published data. Here in, we described predicted 
transcription factors that bind to our in vitro rearranged D645 JCPyV. Although differences in 
transcription factor binding sites were identified when comparing the NCCRs of D645, Mad-1, 
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urine-derived, and CY JCPyV, the exact role of these distinct host transcription factor binding 
site have yet to be described as being critical for the replication, reactivation, and 
rearrangement of archetype JCPyV in permissive cells. Thus far, of the predicted transcription 
factors produced by PROMO in our study, eight have been experimentally shown by different 
groups to play regulatory roles in JCPyV transcription, including NFI/CTF (170, 191), c-Jun 
(119), PURA (30, 37, 38, 129), C/EBP beta (200, 252), NF-1(137, 170), SpiB (156, 158), AP-
1(204), and RelA (190, 205, 252, 255). Current studies in our laboratory are focused on utilizing 
these predicted transcription factor binding sites to demonstrate the importance of host 
transcription factors in the natural history of JCPyV infection and PML pathogenesis. Future in 
vitro studies to characterize these sixteen transcription factors will be done to conclusively 
demonstrate their importance in JCPyV transcription regulation.  
 
Conclusions 
Although debatable, independent groups have demonstrated the presence of archetype and/or 
rearranged JCPyV in the brains of immunocompetent persons and patients that suffer from 
neurological disorders other than PML (63, 73, 228, 236, 250). These data suggest that the 
presence of JCPyV within the brain may be independent of one’s immune status and may occur 
during primary JCPyV infection. Collectively, our in vitro data suggest that RPTE, HBMVE, and 
HBCA cells may be sites in which archetype JCPyV may remain latent after primary infection. 
Utilizing our methods identified in this report, we are now able to generate an archetype JCPyV 
stock, which can be utilized for further studies focused on rearrangement, reactivation, and 
ultimately PML pathogenesis. It is known that JCPyV has a strict restricted cellular tropism, thus 
our finding that archetype JCPyV can productively infect and replicate in primary HBMVE and 
RPTE cells may provide clues into the cellular and molecular mechanisms of archetype JCPyV 
tropism. The nonproductive infection of archetype JCPyV in HBCA cells, when compared to 
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previous data demonstrating productive infection of rearranged JCPyV in HBCA cells, may help 
us to understand the importance of the cellular environment for infection based on the JCPyV 
NCCR structure, which will allow development of therapeutics for PML. Our results support the 
idea that JCPyV may have a propensity for maintaining a persistent infection in non-glial cells 
(6). Archetype JCPyV may lay latent in peripheral organs such as the kidneys, in HBMVE cells 
that line the BBB, or HBCA cells within the brain of asymptomatic persons, where 
immunosuppression can lead to reactivation and rearrangement into the neurotropic form. 
Although we demonstrated in vitro rearrangement of archetype JCPyV, the exact mechanism of 
rearrangement is unknown. Thus studies are currently underway to delineate the possible 
molecular mechanisms of rearrangement and reactivation of archetype JCPyV. Our overarching 
goal is to elucidate the transcription factor profile of cells permissive to JCPyV infection in hopes 
of understanding the cellular environment conducive to reactivation and rearrangement.  
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Materials and Methods  
Cell culture 
COS-7 cells were maintained as described previously (94). Primary HBMVE cells and primary 
HBCA cells were purchased from Cell Systems Corporation and maintained as previously 
described (35, 240), while primary RPTE cells (Cat #4100) were purchased from Sciencell. 
HBCA, HBMVE, and RPTE cells between passages P6 and P8 were used in all experiments. 
Fetal brain tissues were obtained from the Kapiolani Medical Center for Women and Children 
(KMCWC), after receiving approval from the KMCWC Institutional Review Board and the 
University of Hawai’i Committee on Human Studies (UHCHS) and processed as described 
previously to generate PHFG cells (32).  
 
Virus  
Archetype JCPyV was isolated from the urine of healthy volunteers after obtaining written 
consent and study approval by UH-CHS. Urine was received from patients, stored at 4oC no 
longer than 12 hr, and processed as previously described (71). Urine samples were not pooled. 
DNA was extracted using Qiagen QIAprep Spin Miniprep Kit according to the manufacturer’s 
protocol from 100 µL of processed sample. Urine-isolated JCPyV was then quantitated by real-
time PCR (qPCR) (32) and confirmed by  sequencing NCCR as described previously (202). To 
generate archetype virus stock, COS-7 cells were infected with urine-derived JCPyV and 
harvested at day 35 after infection. Virus isolation and purification was conducted as previously 
described (32). Virus was then quantitated by HA assay (234) and qPCR, and confirmed by 
NCRR sequence analysis.  
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HA assay 
VP1 is the major capsid protein of the JCPyV and it is responsible for the attachment to cells 
and agglutinates  human type O erythrocytes (234). Human type O erythrocytes were 
centrifuged at 2,500 rpm for 10 min at 4oC, washed twice in Alsever’s buffer (20 mM sodium 
citrate, 72 mM NaCL, 100 mM glucose, pH 6.5 adjusted with acetic acid), and suspended in 
Alsever’s buffer at a final concentration of 0.5%. Serial two-fold dilutions of virus suspensions 
were prepared in Alsever’s buffer. 50 µL of viral suspension and an equal volume of RBC were 
added to each well of a 96-well “U” bottom microtiter plate and incubated at 4oC for 3-6 hr, with 
a final volume of 100 µL. The final dilution of virus suspension that agglutinates red blood cells 
was considered the end point of the titration and read as the reciprocal of that dilution. The end 
point dilution is considered 1 hemagglutination (HA) unit, with the estimated ratio of infectious 
particles being approximately 104 to 1 HA unit (33, 173). 
 
JCPyV infection 
1x105 COS-7, RPTE, HBMVE, HBCA, and PHFG cells were seeded in tissue culture treated 35 
mm plates to study viral kinetics, and 1x106 cells in T-75 tissue culture flasks were seeded for 
protein extraction. Additionally, 5x104 cells were seeded in each well of a 24-well plate 
containing cover slips for immunofluorescence assay (IFA). At 80-90% confluency, 
aforementioned cells were either mock-infected with medium only, or inoculated with 41 HA 
JCPyV per 1x105 cells. Initial virus inoculums were measured using qPCR, prepared at 
appropriate concentrations, and added into designated plates, wells, or flasks and returned to 
an incubator (37oC with 5% CO2) for 24-hr adsorption for archetype JCPyV and 2-hr adsorption 
for rearranged JCPyV. Each plate, well, or flask was then washed twice with 1X PBS to remove 
unadsorbed virus followed by replenishment of fresh medium. Wells, plates, and flasks were 
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kept at 37oC with 5% CO2 until time of cell harvest at designated time points. Culture medium 
was changed every 2 days. 
 
Serial passaging of COS-7 cells for 665 days 
At 80-90% confluency, cells were infected with 41 HA per 1x105 cells of archetype JCPyV per T-
75 tissue culture flask. Infected cells were passaged every 10 days, and cell lysates were 
collected for DNA and RNA analysis.  
 
Reinfection of naïve cells 
At 80-90% confluency, cells were infected with 41 HA per 1x105 cells of archetype JCPyV per T-
75 tissue culture flask. Infected cells were passaged every 10 days, and cell lysates were 
collected for DNA and RNA analysis. For the reinfection of naïve HBMVE or RPTE cells,  
thirty five days after infection, infected cells were subjected to virus isolation and purification as 
previously described (32). Supernatant/initial virus inoculum was measured using qPCR and 
naïve HBMVE or RPTE cells were reinfected as mentioned above. 
 
DNA and RNA extraction and quantitative analysis 
Low molecular weight DNA and total RNA were extracted from mock- and archetype JCPyV-
infected cells from 35 mm plates harvested on days 1 (24 hr after infection), 5, 10, 15, 20, and 
25 after infection as previously described (32). cDNA was synthesized from 1 µg of cellular RNA 
using Bio-Rad iScript cDNA synthesis kit following the instructions provided by the 
manufacturer. JCPyV DNA or cDNA was amplified using 2 µL of template DNA or cDNA, 10 
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pmol each of forward and reverse primers, and probe specific for JCPyV TAg and for VP1 
genes in a final reaction volume of 20 µL as previously published by our group (32). qPCR was 
conducted using a Bio-Rad iCycler iQ™ Multicolor Real-Time PCR Detection System. Analysis 
was conducted via Bio-Rad iCycler iQ™ Multicolor Real-Time PCR Optical System Software 
Version 3.1.  
 
PCR amplification and sequence analysis 
JCPyV NCCR was amplified using 2 µL of template DNA and primers JRR-25 and JRR-28 as 
described previously (202). PCR products were separated on a 2% agarose gel, visualized with 
ultraviolet light, and purified by QIAquick PCR purification column and sequenced for positive 
identification of archetype JCPyV. Utilizing PROMO, a web-based program which utilizes the 
TRANSFAC database of transcription factor binding motifs, potential transcription factor binding 
sites were predicted for JCPyV sequenced NCCRs (163). 
 
Immunoprecipitation and western immunoblot  
Total cellular protein was extracted from mock-infected and JCPyV-infected cells and separated 
by centrifuging the lysate for 30 min at 12,000 rpm at 4oC. Protein concentrations were assayed 
using Bio-Rad Quick Start Bradford Protein Assay. T antigen from 250 µg of total protein 
extracts were immunoprecipitated using 60 µL of protein G Plus/Protein A Agarose suspension 
and 10 µL (2 µg) of anti-SV40 T antigen mouse mAb at 4oC overnight (35). Immunoprecipitated 
protein was separated on SDS-PAGE, transferred onto nitrocellulose membranes, and 
incubated overnight using anti-SV40 T antigen mouse primary antibody (1:1,000) as described 
previously (35). Following incubation with secondary antibodies conjugated with IRDye 680 
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(1:10,000) (Li-Cor Biosciences), the membranes were visualized using the Li-Cor Odyssey 
imaging system according to manufacturer’s instructions (199).  
 
Immunofluorescence assay  
HBMVE, RPTE, and HBCA cells were seeded on coverslips in 24-well pates (5x104 cells/well). 
Cells were either mock-infected with medium only, or infected with JCPyV. Cell preparation and 
staining with various primary antibodies were conducted as previously described (35). 
Fluorescent cells were examined using an Axiocam MRm camera mounted on a Zeiss Axiovert 
200 microscope equipped with the appropriate fluorescent filters and objectives.  
 
Transmission electron microscopy   
After 15 days, mock-infected and JCPyV-infected HBMVE and RPTE cells cultured in 35 mm 
plates were washed twice with cold 1 X PBS, treated with serum-free trypsin-EDTA solution and 
spun at 13,000 rpm for 10 mins at 4oC. The supernatant was decanted and the cell pellet was 
fixed with 2.5% glutaraldehyde in 0.1M sodium cocodylate buffer, pH 7.4, for 1-2 hr at room 
temp. Fixed samples were processed using a Hitachi HT7700 all-digital 120 kV Transmission 
Electron Microscope (TEM) with AMT 2k x 2k CCD camera and tomography option for 
conventional TEM. 
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Figure Legends  
 
Figure 1. Urine-isolated archetype JCPyV efficiently replicates in COS-7 cells: Semi-
confluent COS-7 cells were infected with either (A) 41 HA urine-isolated archetype or (B) 5 HA 
Mad-1 JCPyV and cells were harvested at indicated time points for DNA and RNA extraction. 
Viral TAg and VP1 genome copies, and RNA transcripts were quantitated by qPCR and qRT-
PCR, respectively. HA assay was conducted using human ‘O’ blood group positive RBC, to 
confirm the production of archetype and rearranged type JCPyV virions. HAU, hemagglutination 
assay units. 
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Figure 2. Archetype JCPyV efficiently replicates in primary HBMVE cells: HBMVE cells were 
infected with 41 HA of COS-7 cells propagated urine-isolated archetype JCPyV for 24 hr and cells 
were harvested at indicated time points. DNA and RNA were extracted and viral TAg and VP1 (A) 
genome copies and RNA transcripts were quantitated by qPCR and qRT-PCR, respectively. (B) 
IP followed by WB analysis was conducted on JCPyV infected HBMVE cell lysates harvested at 
day 15 after infection using anti-SV40 TAg mouse mAb. C, control uninfected; I, infected. (C) IFA 
was conducted on HBMVE cells infected with archetype JCPyV at day 15 after infection and cells 
were stained using anti-JCPyV VP1 mouse mAb; inset indicates secondary Ab only; VP1 (green) 
and DAPI (blue); scale bar, 20 µm. (D) TEM was conducted for detection of JCPyV virions in the 
nucleus of primary HBMVE cells. Scale bar, 500 nm; inset scale bar, 250 nm. M, mitochondria; 
Nu, nucleus; rER, rough endoplasmic reticulum. 
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Figure 3. Archetype JCPyV efficiently replicates in primary RPTE cells: RPTE cells were 
infected with 41 HA of COS-7 cells propagated urine-isolated archetype JCPyV for 24 hr and cells 
were harvested at indicated time points. DNA and RNA were extracted and viral TAg and VP1 (A) 
genome copies and RNA transcripts were quantitated by qPCR and qRT-PCR, respectively. (B) 
IP followed by WB analysis was conducted on JCPyV infected HBMVE cell lysates harvested at 
day 15 after infection using anti-SV40 TAg mouse mAb. C, control uninfected; I, infected. (C) 
Immunofluorescence staining was conducted on HBMVE cells infected with archetype JCPyV at 
day 15 after infection and cells were stained using anti-VP1 mouse mAb; inset indicates 
secondary Ab only; VP1 (green) and DAPI (blue); scale bar, 20 µm. (D) TEM was conducted for 
detection of JCPyV virions in the nucleus of primary RPTE cells. Scale bar, 500 nm; inset scale 
bar, 250 nm. Nu, nucleus. 
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Figure 4. Reinfection of naïve HBMVE and RPTE cells demonstrates production of 
infectious virions: Naïve HBMVE and RPTE cells were infected with 41 HA of archetype JCPyV 
isolated from previously infected HBMVE and RPTE cells, and cells were harvested at indicated 
time points for DNA and RNA extractions. Reinfection of isolated archetype JCPyV in HBMVE 
cells TAg and VP1 (A) genome copies and RNA transcripts. Reinfection of isolated archetype 
JCPyV in RPTE cells TAg and VP1 (B) genome copies and RNA transcripts. 
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Figure 5. Limited replication of archetype JCPyV in primary HBCA: HBCA were infected 
with 41 HA of either COS-7 cells propagated urine-isolated archetype JCPyV or Mad-1 JCPyV, 
and cells were harvested for DNA and RNA extractions on indicated days. Archetype JCPyV 
TAg and VP1 (A) genome copies and RNA transcripts or Mad-1 JCPyV (B) TAg and VP1 
genome copies and RNA transcripts were quantitated by qPCR and qRT-PCR, respectively. (C) 
IP followed by WB analysis was conducted on JCPyV-infected HBCA cell lysates harvested at 
day 15 after infection using anti-SV40 TAg mouse mAb. C, control uninfected; I, infected. (D) 
IFA was conducted on HBCA infected with archetype JCPyV at day 15 after infection and cells 
were stained using anti-SV40 TAg mouse mAb; inset indicates secondary Ab only TAg (green) 
and nucleus (DAPI, blue); scale bar, 20 µm. 
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Figure 6. Archetype JCPyV does not replicate in PHFG cells: PHFG cells were infected with 
41 HA of either COS-7 cells propagated urine-isolated archetype JCPyV or Mad-1 JCPyV, and 
cells were harvested at indicated time points for DNA and RNA extractions. Archetype JCPyV 
TAg and VP1 (A) genome copies and RNA transcripts or Mad-1 JCPyV TAg and VP1 (B) genome 
copies and RNA transcripts were quantitated by qPCR and qRT-PCR, respectively. (C) IP 
followed by WB analysis was conducted on JCPyV-infected PHFG cell lysates harvested at day 
15 after infection using anti-SV40 TAg mouse mAb. C, control uninfected; I, infected. 
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Figure 7. NCCR comparison of archetype JCPyV infected primary cells demonstrate 
conservation in the NCCR but rearrangement in COS-7 cells at 645 days Conventional PCR 
was conducted for JCPyV NCCR with primers JRR-25 and 28. The nucleotide start position at 1 
in the CY, archetype JCPyV [M35834], is that of Yogo et al. [1990]. Mad1, rearranged JCPyV 
[J02227], contains duplicate copies in block A, a 25-bp region containing the TATA box, block C, 
a 55-bp region, and block E, an 18-bp region, to yield a 98-bp tandem repeat. Sequences 
encoding the early proteins (E), large T, small t, and T’, are to the left of the nucleotide start 
position 1. The initial codon for the agnoprotein is at position 270. Sequences encoding the late 
proteins (L), VP1, VP2, and VP3 are to the right of block F. *Archetype JCPyV NCCR sequences 
at 35 days after infection with respective cell types. D645 COS-7, urine-derived archetype JCPyV 
passaged every 10 days demonstrated rearrangement at 645 days after infection, contains one 
base pair substitution in block A, one base pair substitution in block B, an 8 base pair insertion in 
block C, and 5 base pair deletion in block F. 
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Figure 8. Replication kinetics of day 645 rearranged JCPyV infected primary cells (A) 
HBMVE, (B) RPTE, and (C) HBCA cells were infected with 41 HA of D645 rearranged JCPyV, 
and cells were harvested for DNA and RNA extractions on indicated days. JCPyV TAg and VP1 
genome copies and RNA transcripts were quantitated by qPCR and qRT-PCR, respectively. 
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Table 1. Predicted transcription factor binding sites  
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a Common name and Transfac ID of putative binding transcription factors  
b Transcription factors that bind the promoter of D645 COS-7 rearranged JCPyV 
c Transcription factors that bind the promoter of Mad-1 variant of JCPyV 
d Transcription factors that bind the promoter urine-derived archetype JCPyV 
e Transcription factors that bind the promoter of CY JCPyV 
f Experimental evidence demonstrating binding of transcription factors to JCPyV NCCR 
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Supplemental Figure 1. Isolation of archetype JCPyV from urine: (A) Early morning urine 
samples from healthy volunteers were screened for the presence of JCPyV TAg genome and 
were quantitated using qPCR. (B) Amplification of the NCCR by PCR with JCPyV specific NCCR 
primers JRR-25 and 28 and sequence analysis by ClustalW demonstrate percent identity and 
divergence of JCPyV positive patient IDs compared to CY [M35834] and Mad1 JCPyV [J02227].  
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Supplemental Figure 2. JCPyV real-time primers and probes are specific to JCPyV: (A) qRT-
PCR of JCPyV infected COS-7 cells using SV40 TAg specific primers and probe. (B) Comparison 
of SV40 TAg specific primers and probe and JCPyV TAg specific primers and probe.  
 
 
 
 
A 
B 
109 
 
Acknowledgments 
We thank Dr. Richard J. Frisque of the Pennsylvania State University for providing us with COS-
7 cells and assistance in preparing supplemental figure 2, and Ms. Laarni Sumibcay for 
technical assistance. We thank Ms. Tina M. Weatherby Carvalho and the Biological Electron 
Microscope Facility, UHM, and the Histopathology Core and Imaging Core Facility of the 
Research Centers in Minority Institutions Program (G12MD007601), NIMHD/NIH, for use of the 
LI-COR Odyssey imager. We also thank Dr. Moti L Chapagain for assistance during early phase 
of this project. This work was supported by grants from the PML Consortium LLC (120712), the 
Centers of Biomedical Research Excellence, NIGMS/NIH (P30GM114737), the NINDS/NIH, 
(R03NS060647), and Institutional funds. 
 
Author Contributions 
N.L. and V.R.N. designed, analyzed results, and wrote the manuscript. N.L. conducted the 
experiments. N.L. and V.R.N. analyzed data. All authors have read and approved the final 
version of the manuscript. 
 
Competing financial interests: The authors declare no competing financial interests. 
 
 
 
 
 
 
 
110 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
 
EFFECT OF ARCHETYPE JCPYV VP1 MUTATIONS ON REPLICATION KINETICS IN 
PRIMARY BRIAN CELLS AND ITS CONTRIBUTIONS IN MECHANISMS OF JCPYV 
PATHOGENESIS 
 
 
 
 
 
 
 
 
 
 
 
111 
 
Effect of archetype JCPyV VP1 mutations on replication kinetics in primary brain cells 
and its contributions in mechanisms of JCPyV pathogenesis  
 
Nelson B. Lazaga1, 2, Brigitte Bollag3, Richard J. Frisque3, and Vivek R. Nerurkar1, 2, *  
 
 
1Department of Tropical Medicine, Medical Microbiology and Pharmacology, 2Pacific Center for 
Emerging Infectious Diseases Research, John A. Burns School of Medicine, University of 
Hawaii at Manoa, Honolulu, Hawaii 96813, and 3Department of Biochemistry and Molecular 
Biology, The Pennsylvania State University, University Park, Pennsylvania 16801 
 
 
*Corresponding author: Vivek R. Nerurkar, Ph.D. John A. Burns School of Medicine, University 
of Hawaii at Manoa, 651 Ilalo Street, BSB 320G, Honolulu, HI, 96813,  
Phone: (808) 692-1668, Fax: (808) 692-1984, E-mail: nerurkar@hawaii.edu 
 
 
 
 
 
 
112 
 
Abstract 
Background: Progressive multifocal leukoencephalopathy (PML), caused by the polyomavirus 
JC (JCPyV), remains an important cause of morbidity and mortality among AIDS patients. While 
archetype JCPyV is widespread and circulates in humans, only the rearranged type of JCPyV 
causes PML. We have previously demonstrated that urine-derived archetype JCPyV replicates 
in human brain microvascular endothelial (HBMVE) cells. However, the role of the viral capsid 
protein 1 (VP1) coding region in PML pathogenesis is still unclear. Based on our preliminary 
data, we hypothesized that mutations in VP1 will result in JCPyV increased infection and 
replication in HBMVE cells. Methods: Primary HBMVE cells were transfected with 25 ng of 
either parental constructs of archetype JCPyV (CY), rearranged JCPyV (Mad1 or M1), or hybrid 
JCPyV (CYrM1c), which contains an archetype NCCR in the backbone of rearranged JCPyV 
(Mad1) coding region. HBMVE cells were also transfected with 25 ng of either CYrM1c 
constructs with the VP1 mutations CYrM1c-S267F or CYrM1c-L55F. Cells were harvested at 4 
hr and at 3, 5, 10 and 15 days after transfection, and DNA and RNA was extracted to study 
virus replication kinetics using qPCR and qRT-PCR for JCPyV early and late genes, TAg and 
VP1 respectively. In addition, primary human fetal glial (PHFG) cells were transfected with 25 
ng M1, M1-L55F, or M1-S267F, amplified via VP1 PCR, and sequenced. Lysate from PHFG 
cells transfected with M1, M1-L55F, or M1-S267F were sonicated, tittered, and used to reinfect 
PHFG cells to demonstrate production of infectious virions. Lastly, COS-7 cells were transfected 
with 25 ng of CY to propagate infectious virus used to infect HBMVE cells. VP1 and NCCR 
sequence analysis was conducted for each experiment. Results: Input JCPyV TAg and VP1 
DNA was detected for all three JCPyV constructs 4 hrs after transfection. Archetype JCPyV 
(CY) and rearranged JCPyV (Mad1) replication increased steadily over the course of 15 days 
after transfection, whereas increase in replication was not observed using the hybrid JCPyV 
(CYrM1c). Conclusions: These preliminary data demonstrate that archetype JCPyV (CY) and 
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rearranged JCPyV (Mad1) can replicate in HBMVE cells, whereas limited replication was 
observed when HBMVE cells were transfected with the hybrid JCPyV (CYrM1c). Studies are 
ongoing to understand transcription of viral RNA via qRT-PCR, protein production by 
immunoprecipitation followed by western blotting for JCPyV TAg, and NCCR rearrangements 
via sequence analysis. 
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Introduction   
Despite the ubiquitous nature of JCPyV, with reports depicting seroprevalence ranging between 
66% to 92% (242) and up to 40% of the population persistently shedding virus in the urine 
(124), progressive multifocal leukoencephalopathy (PML) is rare and almost always associated 
with an underlying immunosuppressive condition. PML is a fatal demyelinating disease caused 
by the reactivation of latent JCPyV resulting in the lytic infection of oligodendrocytes, the myelin 
producing cells within the CNS. Although JCPyV is generally asymptomatic, factors leading to 
immunosuppression or immune dysfunction, such as the use of immunosuppressive drugs or 
HIV/AIDS, can trigger the reactivation, replication, and lytic infection of JCPyV in 
oligodendrocytes resulting in PML. Currently, there are no treatments for PML and is fatal within 
a few months from onset. The only proven approach to manage PML in affected individuals is 
the reversion of the immune suppression when possible (42, 149). Although JCPyV reactivation 
in individuals with a compromised immune system is associated with PML, the exact 
mechanisms leading to PML remains unknown. 
 
It is thought that active replication results in the accumulation of deletions and duplications 
within the noncoding control region (NCCR) (70, 138, 187) and point mutations in the viral 
capsid protein 1 (VP1 (113, 263) of archetype strains, giving rise to neurotropic rearranged 
stains. Neurotropic rearrangements are independent amongst affected individuals, but these 
rearrangements always occur in the NCCR and often also in VP1 (212).   
 
It is believed that both host (i.e. transcription factors) and viral genetics, NCCR rearrangement 
and VP1 mutations, may contribute to the development of PML. Several studies have reported 
the presence of mutations in the major VP1 in JCPyV isolated from PML patients (113, 225, 
262, 263). These nonpolymorphic (i.e. JCPyV subtype-independent) PML-associated mutations 
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or deletions of JCPyV VP1 include the amino acid positions 50, 51, 55, 60, 61, 122-125, 265, 
267, 269, 271, and 283 (113, 262, 263). Cinque et al reported that the most frequent VP1 
changes involved the amino acids 269 and 55, with VP1 mutants 55F, 267F, and 269F having a 
loss in hemagglutination property (87). These studies suggest the importance of VP1 in JCPyV 
pathogenesis in the context of VP1 mediated immune responses (127, 246), cell attachment, 
and viral entry via sialic acid receptors (36, 135). Although viral isolates with VP1 mutations 
have been demonstrated to be present in individuals with PML, it has not been established 
whether JCPyV with PML-associated VP1 mutations are pathogenic in cells of the CNS.  
 
We have previously demonstrated that rearranged Mad-1 (35) and archetype JCPyV 
(unpublished data) productively infects primary human brain microvascular endothelial 
(HBMVE) cells, cells that line the blood-brain barrier (BBB). Therefore, the objective of this 
study was to assess the relationship between VP1 mutations associated with PML (i.e., mutants 
L55F, S267F, and S269F) and the JCPyV replication kinetics in HBMVE cells.  
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Results and Discussion  
JCPyV VP1 mutants are replication-incompetent in primary HBMVE cells  
To define the replication kinetics of PML-associated JCPyV VP1 mutations in HBMVE cells, we 
transfected primary HBMVE cells with five different JCPyV constructs. These constructs 
included three parental strains and two PML-associated VP1 mutants: 1) CY, consisting of the 
archetype NCCR and coding regions; 2) Mad-1, consisting of the rearranged NCCR and coding 
regions; 3) CYrM1c, consisting of the archetype NCCR and Mad-1 coding regions; and 4) L55F; 
and 5) S267F mutants, consisting of the archetype NCCR and Mad-1 coding regions with the 
amino substitutions in VP1 at positions 55, leucine to phenylalanine, and 267, serine to 
phenylalanine. As expected, Mad-1 transfection of HBMVE cells resulted in an increase in DNA 
and mRNA transcripts of both TAg and VP1 over the course of 35 days (Fig. 1D). Our 
previously published data also demonstrated productive infection of Mad-1 JCPyV in HBMVE 
cells (35). Interestingly, CY transfection of HBMVE cells resulted in a decrease of TAg and VP1 
DNA over 35 days, with the detection of TAg and VP1 mRNA at only day 5 after transfection 
(Fig. 1A). CYrM1c (Fig. 1B), L55F (Fig. 1D), and S267F (Fig. 1E) displayed a similar trend, 
where a gradual decrease in TAg and VP1 DNA was observed over 35 days with detection of 
TAg and VP1 mRNA only at day 5 after transfection.  
 
Glucocorticoid treatment of HBMVE cells fails to enhance JCPyV transcription  
Dexamethasone, a synthetic glucocorticoid, has the ability to suppress interferon responses 
resulting in strong immunosuppressive properties (75, 142, 206). In vivo experiments have 
demonstrated increased virus replication in mammalian cells after dexamethasone treatment for 
Brennan-Krohn polyomavirus (BKPyV) (165), herpes simplex virus 1 (HSV-1) (57, 96), murine 
mammary tumor virus (MMTV) (108, 184), and the retrovirus Moloney murine leukemia virus 
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(MMLV) (222). In rare instances, case reports of JCPyV induced PML in the context of organ 
transplantation has been described as an adverse side effect of glucocorticoid use. In 24 cases 
of PML associated with transplant recipients reported in the literature, nine occurred in renal 
transplant patients, six in bone marrow, 4 in liver, three in heart, and two in lung transplants. All 
of the solid-transplant recipients received immunosuppressive treatment, with eighty-three 
percent of the patients receiving corticosteroids (216). In this study, we demonstrate that 
dexamethasone treatment is not toxic to HBMVE cells (Table 1). The physiological 
concentration of dexamethasone used was based off of previous reports, where 50 ng/mL of 
dexamethasone resulted in an 11-fold increase in BKPyV viral capsid protein expression (165).  
In contrast to BKPyV, HSV-1, MMTV, and MMLV, dexamethasone failed to enhance TAg and 
VP1 transcription of CY, CYrM1c, and Mad-1 JCPyV strains (Fig. 2). The increase in virus 
replication and transcription rate, particularly the late genes expressing structural proteins, of 
BKPyV was attributed to the presence of a functional nonconsensus GRE/PRE sequence and a 
consensus ERE sequence located in the late leader (overlapping the putative agnongene start 
codon) of the BKPyV NCCR (165). It is plausible that the reason dexamethasone treatment of 
JCPyV infected HBMVE cells failed to show enhancement in viral replication and/or transcription 
could be due to the differences in the NCCR of JCPyV and BKPyV, where GRE/PRE and ERE 
sequences have been described in BKPyV but not in JCPyV.  
 
Differences in infection and transfection of CY JCPyV in HBMVE cells  
Cell signaling is strongly activated during viral infection and might facilitate viral uptake and 
appropriate intracellular signaling following binding of viruses to receptors (89). Therefore, 
discrepancies between infection and transfection in JCPyV might be plausible. Interaction 
between the virus and host cell receptor in susceptible cells results in activation and triggering 
of a signaling cascade, which primes a favorable cellular environment for completing the virus 
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life cycle (23). For example, in T-cells, within a minute of HIV-1 infection, more than 200 
phosphorylation sites are modified, potentially altering several cellular processes resulting in an 
environment conducive to virus replication (53). We previously reported that archetype JCPyV 
can productively infect HBMVE cells (unpublished), therefore it was surprising to observe that 
CY transfection in HBMVE cells failed to replicate (Fig. 1A). Utilizing similar methods to 
propagate urine-derived archetype JCPyV, we were able to propagate infectious CY virions 
(Fig. 3A) to corroborate that CY, like urine-derived archetype JCPyV, can infect HBMVE cells. 
Although delayed, CY virions are capable of replicating as TAg and VP1 DNA and mRNA were 
detected by qPCR and qRT-PCR (Fig. 3B). The artificial insertion of exogenous viral DNA into 
cells via transfection is an important, well-established tool. However, one must appreciate the 
natural history of viral infection and the importance of bypassing the initial step of infection. As 
mentioned, binding to the permissive host cell receptor elicits downstream pathways and 
molecules that are important for virus replication. Transfection is a complex process that can 
produce both direct (intended) and indirect (unintended) results, thus having the potential to 
cause biological responses that are unrelated to what is being transfected (109).  
 
Propagation of infectious virions in PHFG cells fails to reinfect naïve HBMVE cells  
To further evaluate the difference between infection and transfection in the context of JCPyV, 
we utilized similar methods in virus propagation for Mad-1 VP1 mutants as previously described 
(35). Herein, virus from previously transfected PHFG cells was used to reinfect naïve HBMVE 
cells. DNA copies from previously transfected PHFG cells was used to calculate the TAg and 
VP1 DNA (2 x 108 average) used to reinfect naïve HBMVE cells (Fig. 4A). Mad-1 S267F and 
Mad-1 strains, but not Mad-1 L55F, had sufficient amount of virus to reinfect naïve HBMVE cells 
for 35 days. As expected, Mad-1 reinfection of naïve HBMVE cells resulted in productive 
infection, showing an increase in both TAg and VP1 DNA and mRNA. In contrast, the Mad-1 
S267F mutant failed to replicate over the course of 35 days.  
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Conclusion 
In vivo data demonstrates JCPyV L55F and S267F VP1 mutations as being the most common 
mutations in CSF-derived sequences. This observation was correlated with the ability of both 
mutations to abrogate JCPyV hemagglutination and binding to peripheral cells and to sialic acid, 
suggesting this loss of function as being advantageous (87). It has been speculated that 
changes in glycan specificity would allow JCPyV to lose its specificity to sialylated glycans 
expressed outside of the CNS (e.g. red blood cells). Interestingly, it has been demonstrated that 
HBMVE cells express α2,3 and α2,6 -linked sialic acid receptors (1). Thus, it is reasonable to 
believe that JCPyV VP1 mutants L55F, S267F, and S267F would not be able to bind and infect 
HBMVE cells. We were unable to demonstrate this possibility due to the fact that transfection of 
JCPyV VP1 mutants L55F, S267F, and S267F failed to replicate and produce infectious virions. 
We were, however, able to demonstrate the propagation of CY virions after transfection in COS-
7 cells and the ability of these virions to infect HBMVE cells. 
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Materials and Methods 
Cell culture 
COS-7 cells were maintained as described previously (94). Primary HBMVE cells were 
purchased from Cell Systems Corporation and maintained as previously described (35, 240). 
HBMVE cells between passages P6 and P8 were used in all experiments. 
 
Plasmids 
CY, CYrM1c, Mad-1, CYrM1c-L55F, and CYrM1c-S267F plasmids were a received as a gift 
from Dr. Richard Frisque (Pennsylvania State University). NCCR and VP1 plasmids sequences 
were  confirmed as described previously (202). To generate CY virus stock, COS-7 cells were 
transfected with CY plasmid and harvested at day 35 after transfection. Virus isolation and 
purification was conducted as described previously, (32) followed by quantitation by qPCR.  
 
DNA transfection 
1x105 HBMVE cells were seeded on 35 mm 6-well plates to study viral kinetics. At 80-90% 
confluency, cells were either mock-transfected with medium only, or transfected with 25 ng of 
either CY, CYrM1c, Mad-1, CYrM1c-L55F, and CYrM1c-S267F plasmid using Lipofectamine® 
LTX & PLUS™ Reagent (Invitrogen), following the manufacturer’s protocol. Six-well plates were 
kept at 37oC with 5% CO2 until time of cell harvest at designated time points. Culture medium 
was changed every 2 days. 
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Dexamethasone treatment 
HBMVE cells were pretreated 24 h with dexamethasone prior to transfection. This was followed 
by continuous treatment until designated harvest time points. Culture media with 
dexamethasone was changed every third day. Dexamethasone was added to the culture media 
just before changing the media.  
 
Reinfection of naïve cells 
Approximately 105 HBMVE or PHFG cells were seeded in each well of the 6-well plates to 
conduct viral kinetics study. At 80-90% confluency, cells were either mock-treated with medium 
only, or infected with 41 HA per 1x105 cells, where 3 mL of medium was used per 35-mm plate. 
Before infection medium from each well or flask was removed leaving medium just enough to 
cover the culture surface in each well/flask. Virus inoculums prepared at appropriate 
concentrations in 100 µL volume were then added into designated wells/flasks. Culture plates or 
flasks were then returned to a 37oC incubator with 5% CO2 for 24 hr adsorption for archetype 
JCPyV, while 2 hr adsorption for rearranged JCPyV. Each well/flask was then washed twice 
with 1X PBS to remove unadsorbed virus followed by replenishment of fresh medium. Plates 
and flasks were then kept at 37oC with 5% CO2 until time of cell harvest at specific time points. 
Cell medium was changed every 2 days. 
 
DNA and RNA extraction and quantitative analysis 
Low molecular weight DNA and total RNA were extracted from mock- and archetype JCPyV-
infected cells grown in 35 mm plates harvested on days 1 (24 hr after infection), 5, 10, 15, 20, 
and 25 after infection as described previously (32). cDNA was synthesized from 1 µg of cellular 
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RNA using Bio-Rad iScript cDNA synthesis kit following the instructions provided by the 
manufacturer. JCPyV DNA or cDNA was amplified using 2 µL of template DNA or cDNA, 10 
pmol each of forward and reverse primers, and probe specific for JCPyV TAg and for VP1 
genes in a final reaction volume of 20 µL as previously published by our group (32). qPCR was 
conducted using a Bio-Rad iCycler iQ™ Multicolor Real-Time PCR Detection System. Analysis 
was conducted via Bio-Rad iCycler iQ™ Multicolor Real-Time PCR Optical System Software 
Version 3.1.  
 
PCR amplification and sequence analysis 
JCPyV NCCR was amplified using 2 µL of template DNA and primers JRR-25 and JRR-28 as 
described previously (202). PCR products were separated on a 2% agarose gel, visualized with 
ultraviolet light, and purified by QIAquick PCR purification column and sequenced for positive 
identification of archetype JCPyV. 
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Figure Legends 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
Figure 1. CY, CYrM1c, and CYrM1c VP1 mutants are replication-incompetent in primary 
HBMVE cells: HBMVE cells were transfected with 25 ng of either (A) CY, (B) CYrM1c, (C) Mad-
1, (D) CYrM1c-L55F, or (E) CYrM1c-S267F JCPyV plasmids. Cells were harvested for low 
molecular-weight DNA and total cellular RNA extraction on indicated days. Viral TAg and VP1 
genome copies and RNA transcripts were quantitated by qPCR and qRT-PCR.  
E D 
C 
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Table 1. Dexamethasone toxicity in HBMVE cells using CellTiter96® AQueous One 
Solution Cell Proliferation Assay 
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Figure 2. Effect of dexamethasone treatment on JCPyV RNA expression: HBMVE cells 
were either treated with 100 ng of dexamethasone for 24 h or treated with PBS before being 
transfected with (A) CY, (B) CYrM1c, or (C) Mad-1. In a 96 well plate, 10,000 HBMVE cells were 
plated per well.  One day before transfection, cells were pre-treated with 100, ng/mL 
dexamethasone.  Twenty-four hours after seeding, transfection reagents were added to each 
well following Invitrogen’s Lipofectamine® LTX & PLUS™ Reagent protocol.  At the designated 
time points days 1, 3, 5 and 10 the percent viable cells, compared to untreated control, were 
assayed using Promega’s CellTiter 96® Aqueous ONE Solution Cell Proliferation Assay System 
following the manufacture’s protocol.  The absorbance at 490 nm was recorded using a 96-well 
plate reader.   
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Figure 3. CY transfected COS-7 isolated virus infects HBMVE cells: Sucrose cushion 
isolated virus was prepared from 35-day COS-7 cells transfected with CY JCPyV. (A) COS-7 
propagated CY JCPyV genome titers were determined by TAg and VP1 qPCR.  (B) 41 HA of 
CY isolated virus from COS-7 cells were used to infect HBMVE cells. Viral TAg and VP1 DNA 
genome copies and RNA transcripts were quantitated by qPCR and qRT-PCR 
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Figure 4. PHFG transfected Mad-1 VP1 mutant isolated virus are replication-incompetent 
after infecting HBMVE cells: PHFG isolated virus was prepared from 35-day PHFG cells 
transfected with Mad-1 L55F, Mad-1 S267F, or Mad-1 JCPyV. (A) Mad-1 L55F, Mad-1 S267F, 
or Mad-1 JCPyV genome titers were determined by TAg and VP1 qPCR.  (B) 41 HA of Mad-1 
S267F or Mad-1 isolated virus from COS-7 cells were used to infect HBMVE cells. Viral TAg 
and VP1 DNA genome copies and RNA transcripts were quantitated by qPCR and qRT-PCR 
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PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY: DEVELOPMENT OF A HUMAN 
POLYOMAVIRUS JC INFECTION MODEL USING HUMANIZED MICE 
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Abstract 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were innoculated with archetype and rearranged 
human polyomavirus JCPyV and the course of ensuing infection was evaluated in a quest to 
develop and characterize an animal model to study the pathogenesis of JCPyV infection. Prior 
to inoculation, human immune cells engrafted in NSG mice were confirmed by flow cytometry 
analysis. NSG mice were inoculated with either archetype JCPyV or rearranged JCPyV by 
intravenous (IV) injection. Blood and urine were collected at days 3, 5, 7, 14, 21, and 28 after 
inoculation and JCPyV viral DNA and TAg protein in NSG mice was detected by real-time PCR 
(qPCR) and flow cytometry, respectively. Our data demonstrate that NSG mice have >50% 
CD45+ human cells as determined by the percentage of human CD45+ cells in the peripheral 
blood by flow cytometry. Both archetype JCPyV and rearranged JCPyV productively infected 
NSG mice. JCPyV TAg DNA was detected as early as day three after inoculation in urine of 
mice, which peaked at day 7 after inoculation. JCPyV TAg DNA was first detected in the blood 
of NSG mice on day seven after inoculation. JCPyV TAg protein was also detected in the blood 
on day 7 after inoculation as measured by flow cytometry. JCPyV TAg DNA was detected in the 
urine and blood of NSG mice up to two weeks after inoculation. This study demonstrates JCPyV 
can infect humanized NSG mice. Future research is focused on the routes of primary infection 
and mechanisms of reactivation after HIV co-infection.  
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Introduction 
The human polyomavirus JC (JCPyV) is the etiological agent of progressive multifocal 
leukoencephalopathy (PML), a rare demyelinating disease of the brain caused by the viral lytic 
infection of oligodendrocytes in immunocompromised individuals. PML remains an important 
cause of morbidity and mortality among immunocompromised patients including patients with 
HIV/AIDS, malignancies, transplant recipients, and individuals treated with immunomodulatory 
drugs.  
 
Studies have reported up to 80% of the healthy human population as being seropositive for 
JCPyV (61). It is thought that individuals are infected early in childhood, and virus is detectable 
in the urine of about 30% of healthy individuals without causing disease (154). JCPyV has a 
strict host tropism dictated by cellular species-specific and tissue-specific factors required for 
viral replication (68). Because JCPyV can only infect humans, in vitro studies have only been 
able to demonstrate JCPyV infection in primary human fetal glial cells (153, 189), human brain 
microvascular endothelial (HBMVE) cells (34) (Lazaga and Nerurkar, unpublished), and human 
renal proximal tubule epithelial (RPTE) cells (Lazaga et al., unpublished data). These in vitro 
systems have been important in elucidating the basic molecular virology of JCPyV and testing 
for various antiviral compounds (251). JCPyV infection in nonhuman primates, owl monkeys 
(Aotus trivirgatus) and squirrel monkey (Saimiri sciureus), fail to demonstrate productive 
infection, as assessed by the lack of TAg and VP1 expression (251). The lack of a suitable 
animal model for JCPyV infection and PML has been a direct result of the inability of JCPyV to 
productively infect and replicate in non-human hosts. Therefore, data on potential primary site(s) 
of infection, areas of latency and reactivation, and the mechanisms involved in rearrangement 
during immunosuppression has been limited due to the absence of a JCPyV animal model.  
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Recently, a novel murine model, NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) reconstituted with 
human hematopoietic stem cells, coined ‘humanized NSG mice’, has been employed to study 
human-specific pathogens (144, 214, 232, 257). In a quest to develop and characterize an 
animal infection model for JCPyV, we inoculated humanized NSG mice with JCPyV and 
evaluated the course of infection. The prospect of using NSG mice to study JCPyV infection is 
supported by the idea that the bone marrow (227) is a likely site of latency and that JCPyV can 
infect human B cells (31). Therefore, we hypothesize that humanized NSG mice can be 
productively infected by JCPyV.  
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Results  
Characterization of humanized mice 
Upon receiving the NSG mice, peripheral blood was collected from tail vein and blood 
leukocytes were tested for human CD45 by flow cytometry. The NSG mice used in this study 
were human CD45+, where the total percent of human leukocytes in the blood prior to 
inoculation ranged from 35-57%. Human immune cell lineage engraftment is expressed as the 
frequency of human CD45 cells, with CD19+ B cells ranging from 45-68%, CD4+ T cells ranging 
from 14-23%, and CD8+ T cells ranging from 8-14% (Fig. 1A). Mice were also analyzed for 
human immune cell engraftment 2 months after inoculation, where the total percent of human 
CD45+ cells ranged from 45-71% (Fig. 1B).  
 
JCPyV infects humanized NSG mice 
To test the presence of JCPyV DNA in humanized NSG mice, 30 week old female mice were 
inoculated via tail vein with either a single dose of 5000 HAU archetype or rearranged Mad-1 
JCPyV and blood was first collected via tail vein 3 days after inoculation and once a week 
thereafter. JCPyV DNA was detected and quantitated from whole blood using JCPyV TAg and 
VP1 qPCR. All mice were positive for either JCPyV TAg and/or VP1 DNA in blood (Table 1.) up 
to two weeks after inoculation, with virus load peaking at 7 days after inoculation. JCPyV TAg 
DNA was detected in one of five mice at day 3 after inoculation. JCPyV TAg DNA copies 
detected on day 7 included one archetype JCPyV infected mouse with 4.33x105 copies per µg 
of DNA and two Mad-1 JCPyV infected mice with 6.86x103 and 8.99x105 copies per µg of DNA. 
JCPyV VP1 was detected in all archetype JCPyV inoculated mice ranging from 1.32x102 to 
4.95x103 copies per µg of DNA and one Mad-1 JCPyV inoculated mouse with 8 copies per µg of 
DNA detected on day 7. By day 14, JCPyV TAg DNA was detected in all archetype JCPyV 
140 
 
inoculated mice with DNA detected ranging from 2 to 1.53x105 copies per µg of DNA, while 
Mad-1 JCPyV DNA was detected in one mouse with 2.19x102 copies per µg of DNA. On day 14 
two archetype JCPyV infected mice had detectable JCPyV VP1 DNA at 1 and 3 copies per µg 
of DNA. All blood samples were JCPyV RNA negative at all time points after inoculation.  
 
To examine if humanized NSG mice shed virus after inoculation, urine was collected from mice 
on days 3, 5, 10, 14, 21, and at least once a week thereafter and up to 98 days after inoculation 
(Table 2.). The quantity of JCPyV DNA detected in the urine of archetype JCPyV infected mice 
ranged from 4.86x103 to 6.32x107 copies per µL of urine. The quantity of JCPyV DNA detected 
in the urine of Mad-1 infected mice ranged from 261 to 4.64x103 copies per µL of urine. 
Although JCPyV detected in the blood and the urine did not coincide, all animals had detectable 
JC viral DNA present in blood or urine within the first 2 weeks of inoculation. JCPyV was not 
detectable in urine in either archetype or Mad-1 infected animals after 2 weeks of inoculation 
and JC viral DNA was not detected in the blood or urine of the control animal at any time during 
the experiment.  
 
To further verify that JCPyV infects human CD45+ engrafted cells, JCPyV TAg protein was 
detected by flow cytometry. On day 7 after inoculation, JCPyV TAg protein was observed in 
human immune cells engrafted in three of five NSG mice, two archetype inoculated mice and 
one Mad-1 infected mouse (Fig 2.). As in human infection, mice were asymptomatic when 
inoculated with either type of JCPyV.  
 
To determine if JCPyV was sequestered in tissues of humanized NSG mice, organs were 
analyzed for the presence of JCPyV viral DNA. Kidney, brain and bone marrow were collected 
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and analyzed using JCPyV TAg and VP1 qPCR. Of the three archetype inoculated humanized 
NSG mice, JCPyV viral DNA was detected in the kidney of two mice, whereas JCPyV viral DNA 
was detected in both Mad-1 inoculated humanized NSG mouse kidneys. JCPyV viral DNA was 
not detected in the control animal kidney. Brain and bone marrow were also negative for JCPyV 
viral DNA in all animals.  
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Discussion 
Although it has been determined that JCPyV is the causative agent of PML, the route of primary 
infection and viral dissemination has yet to be fully elucidated. Although in vitro systems have 
been important in elucidating the basic molecular virology of JCPyV, understanding the natural 
history of JCPyV infection can only be answered utilizing a suitable animal model.  To better 
understand the mechanisms that lead to JCPyV infection and dissemination, our goal was to 
determine JCPyV infection of human lymphocytes engrafted in a humanized NSG mouse 
model.   
 
JCPyV is a ubiquitous virus thought to asymptomatically infect individuals early in life resulting 
in a subacute chronic infection of the kidney. In approximately 30% of individuals, virus is shed 
in the urine. Like for humans, JCPyV DNA was detected in the urine of mice for up to two weeks 
after infection and in the kidney after necropsy. It is thought that JCPyV disseminates 
throughout the body by a hematogenous route of infection, finding its way to secondary sites 
like the tonsils, brain, kidney, and bone marrow. Previously published data have demonstrated 
the infection of B cells by JCPyV in vitro (31) and the presence of JCPyV infected B cells in vivo 
(166). Our data demonstrates a proof of concept where human B cells in a humanized NSG 
mouse model can be infected with JCPyV. Detection of JCPyV DNA in the kidney after 
necropsy may demonstrate sequestration of either JCPyV associated B cells and/or cell free 
virus. Because JCPyV is a human-specific pathogen, the presence of JCPyV DNA in the kidney 
of inoculated animals is most likely due to virus being sequestered prior to being excreted in the 
urine. Furthermore, the absence of JCPyV DNA in the brain might suggest that trafficking of 
JCPyV infected B cells and/or cell free virus across the blood brain barrier may be restricted due 
to yet to be determined mechanisms. The absence of JCPyV DNA in other organs may be due 
the low levels of replication of JCPyV in B cells and the ability of JCPyV infected B cells to traffic 
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to secondary site and either sequester or find resident cells to infect due to the inability of 
JCPyV to infect murine cells. Although this model has limitations, such as a lack of persistent 
infection and sequestration in organs due to the apparent inability of JCPyV to infect murine 
cells, NSG mice could be used as a model to further study JCPyV immune responses and 
infection in the blood. A recent report demonstrated the generation of both humoral and cellular 
immune responses, although at low levels, against Mad-4 and CY JCPyV in NSG mice with 
engrafted human thymus (226). Furthermore, studies examining JCPyV in the blood have 
yielded inconsistent results. There are conflicting reports regarding the detection of JCPyV DNA 
by PCR in the PBMC in immunocompetent individuals, ranging from 0-83% (56, 233). In HIV-
infected individuals without PML, JCPyV DNA detected in PBMCs varied from 0 -38%, while in 
patients with advanced AIDS and PML (52, 58, 59, 188, 233), JCPyV DNA was found in the 
PBMCs of 75-89% of these individuals (72, 233). Such reports, as well as our current data, lay 
the foundation for future studies where NSG mice could be used to study the immune response, 
viremia, and viruria in JCPyV and HIV coinfection, as well as in other cases of 
immunosuppression, such as during the use of monoclonal antibodies.  
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Materials and Methods 
Humanized NSG mice 
Humanized NOD/scid-IL-2Rγc
null mice were obtained from The Jackson Laboratory and housed 
in a specific-pathogen-free animal facility at the John A. Burns School of Medicine, University of 
Hawaii at Manoa. All mice were maintained in sterile isolator cages, and fed sterile food and 
water.  
 
Flow cytometry 
Flow cytometry was conducted for the identification of CD45+ human peripheral blood 
leukocytes from 29-week old NSG mice before inoculation. Flow cytometry was conducted for 
the identification of JCPyV TAg in peripheral blood of NSG mice one week post JCPyV 
inoculation. Peripheral blood was collected from tail vein in EDTA-coated tubes. Blood 
leukocytes were tested for human pan-CD45, CD3, CD4, CD8, and CD19 markers as a five-
color combination. Antibodies were obtained from Invitrogen (CD45, Cat# MHCD4501), BD 
Biosciences (CD8, Cat# 341051 and CD19, Cat# 555413), and CALTAG Laboratories (CD3, 
Cat# MHCD0305 and CD4, Cat# MHCD0417). Results were expressed as percentages of total 
number of gated lymphocytes.  
 
Immunohistochemistry 
Brains and kidneys were removed immediately after euthanasia. Brain and kidney from each 
mouse was fixed in 4% paraformaldehyde overnight, followed by an overnight incubation in 30% 
sucrose-PBS overnight. Brains and kidneys were then frozen in OCT compound.  
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JCPyV inoculation 
Archetype JCPyV was isolated from a healthy volunteer and propagated in COS-7 cells (Lazaga 
and Nerurkar, unpublished), while Mad-1 JCPyV was propagated in PHFG cells. Virus titers 
were determined by qPCR and HA assay. At 30 weeks of age, female mice were injected via tail 
vein with either a single dose of 5,000 HAU archetype JCPyV or 5,000 HAU rearranged Mad-1 
JCPyV. Blood was first collected via tail vein 3 days after inoculation and once a week thereafter 
for 12 weeks. Urine was collected on days 3, 5, 10, 14, and once a week thereafter.  
 
DNA and RNA extraction and quantitative analysis of viral DNA 
DNA was extracted from mock- and JCPyV-inoculated mice blood and urine using the QIAamp 
DNA Mini Kit (Cat #51306, Qiagen, CA). The DNeasy Blood and Tissue Kit (Cat #69504, 
Qiagen, CA) was used following the manufacturer’s instructions for DNA extraction from organs. 
Total RNA from blood was extracted using the RNeasy Protect Animal Blood Kit (Cat #73224, 
Qiagen, CA) and cDNA was synthesized from 1 µg of toal RNA using iScript cDNA synthesis kit 
(Cat#170-8890, Bio-Rad) following the instructions provided by the manufacturer. JCPyV DNA 
or cDNA were amplified using 6 µL of template, 10 pmol each of forward and reverse primers, 
and probe specific for JCPyV TAg and for VP1 genes in a final reaction volume of 20 µL, as 
described previously (34). Thermal cycling conditions were followed as described previously 
(35). Real-time PCR was conducted using an Applied Biosystems 7500 Real-time PCR 
Detection system. Analysis was conducted via Applied Biosystems 7500 Software v2.0.5. All 
values above 1 copy was considered positive (226).  
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Figure Legends 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Characterization of humanized NSG mice. Mice were bled to detect human cell 
engraftment. (A) Cells stained with antibodies against B cell marker CD19 and T cell markers 
CD4 and CD8 expressed as frequency of human CD45 cells. (B) Peripheral blood cells were 
stained with antibodies against human panleukocyte marker CD45 from 29 week old NSG mice 
when first received. The percent of positive cells when gated for CD45 is indicated in the bottom 
right of each panel. 
A 
B 
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Figure 2. Detection of JCPyV TAg protein in peripheral blood of humanized NSG mice. 
Peripheral blood was collected one week post-infection and cells were stained for intracellular 
JCPyV TAg. The percent of JCPyV TAg positive cells by intracellular staining is indicated in the 
bottom right of each panel.  
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Table 1. Detection of JCPyV TAg and VP1 DNA in peripheral blood of humanized NSG 
mice.  
 
Mice ID  D3 D7 D14 D21 D28 
 
4 TAg ND ND ND ND ND 
 VP1 ND ND ND ND ND 
 
1 TAg ND 105* 101 ND ND 
 VP1 ND ND 100 ND ND 
 
2 TAg ND ND 103 ND ND 
 VP1 ND 103 101 ND ND 
 
3 TAg ND ND 103 ND ND 
 VP1 ND 103 ND ND ND 
 
5 TAg 103 105 102 ND ND 
 VP1 ND ND ND ND ND 
 
6 TAg ND 103 ND ND ND 
 VP1 ND 101 ND ND ND 
 
*copies per µg of DNA; ND, not detected  
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Table 2. Detection of JCPyV TAg DNA in urine of humanized NSG mice.  
 
Mice ID D3 D5 D10 D14 D21 
      
4 NC NC NC ND ND 
      
1 NC NC 102* ND ND 
      
2 102 103 107 ND ND 
      
3 102 NC 102 ND ND 
      
5 NC 103 NC ND ND 
      
6 102 103 102 ND ND 
 
*copies per µL of urine; ND, not detected; NC, not collected 
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Table 3. Detection of JCPyV TAg and VP1 DNA in organs of humanized NSG mice.  
 
Mice ID  Kidney 
  
4 TAg ND 
 VP1 ND 
  
1 TAg 103 
 VP1 ND 
  
2 TAg ND 
 VP1 ND 
  
3 TAg 102 
 VP1 ND 
  
5 TAg 103 
 VP1 104 
  
6 TAg 104 
 VP1 103 
 
*copies per µg of DNA; ND, not detected. Brain and bone marrow were negative for JCPyV TAg 
and VP1 DNA.  
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CHAPTER 6 
 
OVERVIEW, LIMITATIONS, AND FUTURE DIRECTIONS 
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Overview and limitations 
The ubiquitous human polyomavirus JC (JCPyV) is the causative agent of progressive 
multifocal leukoencephalopathy (PML), a fatal demyelinating disease of the central nervous 
system (5, 195). Although rare in the general healthy population, in immunocompromised 
individuals, PML can result in severe disability or death caused by the lytic infection of 
oligodendrocytes (24, 196). If left unmanaged, the mortality rate is 30-50% within three months 
of diagnosis and although intervention can improve the chance of survival, it is likely that some 
significant neurological deficits will occur (24). PML is primarily seen in patients with HIV/AIDS, 
with approximately 5% of HIV/AIDS patients succumbing to PML, but has also been described 
in case reports in individuals with hematologic malignancies and individuals taking 
immunosuppressive or immunomodulatory therapies (148, 161, 216, 238). Of the best 
described instances of immunomodulatory therapies associated with PML is natalizumab 
(Tysabri®) used to treat multiple sclerosis patients. As of September 2016, approximately 
161,300 patients received natalizumab, with 698 treated patients with a confirmed PML 
diagnosis (46). Interestingly, no PML cases have been reported in MS patients prior to the 
introduction of natalizumab. 
 
JCPyV can be categorized into two types based on the structure of the non-coding control 
region (NCCR), the archetypal form, which contains 6 regions designated A-F, and the 
rearranged forms, which contains deletions and/or duplications (138, 260). Archetype JCPyV is 
largely detected in the kidney and shed in the urine in approximately 30% of immunocompetent 
individuals, while the rearranged form is predominantly detected in the brain and CSF of PML 
patients (61, 133, 154). Because asymptomatic shedding of JCPyV in the urine can be seen in 
both healthy individuals and immunosuppressed patients (4, 121, 122) the kidney is thought to 
be the major organ of JCPyV persistence during latency (39, 123). While the archetypal form of 
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the virus is found within the kidneys and urine of healthy individuals and individuals affected with 
PML (139, 260), the rearranged form is predominantly found within the cerebral spinal fluid 
(CSF) and brain tissues of patients with PML. Although the rearrangement of the JCPyV NCCR 
is important in the pathogenesis of PML, the mechanism by which this rearrangement occurs 
remains unknown (150). However, it is thought that rearrangement of the NCCR and point 
mutations in the capsid protein VP1 of archetype strains are a result of active replication (70, 
113, 138, 187, 263).  
 
Understanding the mechanisms underlying the development of PML has been hampered by the 
inability to conclusively delineate the sites of JCPyV latency and reactivation in humans, the 
inability to demonstrate rearrangement of archetype JCPyV in an in vitro replication model, and 
the absence of an in vivo animal model to study JCPyV pathogenesis. The long-term objective 
of the described research was to delineate the natural history of archetype JCPyV infection, 
reactivation, and rearrangement for evidence based treatment for PML.  
 
Chapter 3 is dedicated to understanding the infection of archetype JCPyV in primary cells and to 
decipher how NCCR rearrangement may be induced in vitro. JCPyV has been detected in 
different tissues and organs in the human body including the tonsils (166, 168), kidney (227, 
261), bone marrow (227), brain (227), spleen (227) and gastrointestinal tract (192), however, it 
is not clear which specific cell type(s) within the tissues and organs infected with JCPyV are 
permissive to infection and therefore a milieu to archetype JCPyV reactivation and 
rearrangement (49, 114, 247). To date, no experimental studies have been conducted to 
demonstrate infection of urine-derived archetype JCPyV in RPTE cells.  
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The difficulty in delineating the cell types susceptible to archetype JCPyV infection has been a 
result of its restricted host cell range in vitro (70, 94, 114, 181). To address issues with the 
limited host cell tropism that JCPyV displays, studies have either focused on, but not limited to, 
using transformed cell lines to drive the replication of JCPyV and/or introducing JCPyV DNA via 
a plasmid based system. A previous study demonstrated the expression of JCPyV TAg protein 
in RPTE cells but did not demonstrate the presence of DNA, RNA, or JCPyV virions (152). 
Although transfection can address the involvement of intracellular components, like DNA-
binding proteins, in JCPyV transcription and DNA replication, transfection bypasses the 
question of binding potential of JCPyV to host cell receptors involved in entry of permissive cell 
types.  
 
The host cell range of archetype JCPyV is strictly restricted in cultured cells, where researchers 
have demonstrated poor to moderate replication of archetype JCPyV in transformed cell lines, 
such as PHFG cells transformed with an origin-defective mutant of simian virus 40 (POJ-19) 
and simian kidney cells transformed with an origin-defective mutant of SV40 (COS-7) cells, 
respectively (50, 95). In vitro data indicates that various archetype JCPyV DNA clones can 
initiate efficient virus replication with the conservation of the NCCR after transfection in COS-7 
cells (95). In contrast, it has been demonstrated that rearranged Mad-1 JCPyV can efficiently 
replicate in primary cells, including PHFG and HBMVE cells (35). Therefore, it has yet to be 
determined if archetype JCPyV can infect and replicate in primary RPTE cells. Our data, for the 
first time, clearly demonstrated the productive infection of archetype JCPyV in RPTE cells.  
 
The exact mechanisms and events leading to NCCR rearrangement has yet to be determined. It 
has been suggested that the pathogenic rearranged form may be generated during virus 
replication, yielding the ability to acquire new tissue tropism and greater pathogenic potential 
159 
 
(49, 201). It has been established that functional TAg is required for JCPyV replication. This has 
been confirmed by the observation that mutations in the TAg-coding region of JCPyV cannot 
commence a lytic infection.  
 
Utilization of COS-7 cells to produce large amounts of progeny JCPyV after transfection with 
conservation of the NCCR in DNA has been demonstrated (94). Archetype JCPyV transfected 
COS-7 (94), COS-7 cells constitutively expressing HIV-1 Tat (COS-tat) (179), and primary 
human fetal glial cells constitutively expressing JCPyV TAg (POJ-19) have been subjected to 
long term cultures (49), up to 72 days after transfection, to demonstrate continuous production 
of JCPyV progeny, but did not demonstrate rearrangement of the NCCR. We have recently 
demonstrated in vitro rearrangement of urine-derived archetype JCPyV after infection in COS-7 
cells 645 days after infection, thus in vitro rearrangement of archetype JCPyV is possible in 
transformed cells expressing TAg.  
 
TAg contains several intrinsic biochemical activities and binds specific cellular proteins required 
for JCPyV replication. The N terminus of TAg contains a DnaJ domain, which contributes to 
efficient viral replication, although it is not clear how this materializes (27). In addition to the 
DnaJ domain, TAg contains a retinoblastoma-associated protein (RB)-binding LXCXE motif, a 
threonine-proline-proline-lysine (TPPK) motif, a nuclear-localization sequence (NLS), a DNA-
binding domain (DBD), and a helicase domain. The functions of these domains and motifs have 
been previously described to play important roles in the replication of JCPyV and /or other 
polyomaviruses. In short, the J domain cooperates with the LXCXE motif to disrupt the 
interaction between RB and the E2F family transcription factors in order to promote cell cycle 
entry and progression (224). The phosphorylation of the threonine residue in the TPPK motif 
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has been demonstrated to be required for TAg-mediated viral DNA replication (248), while the 
NLS binds specifically to KPNA family importin homologues (51). The DBD and helicase 
domains are required for viral replication and recruit cellular DNA replication factors. The DBD 
binds the replication factors DNA polymerase-α catalytic subunit (POLA), the replication protein 
A complex (RPA), and the DNA primase complex (PRIM). Lastly, the helicase domain binds the 
molecules EP300, CREBBP, p53, and DNA topoisomerase 1 (TOP1) (51).  
 
Due to the importance of TAg in JCPyV replication, it is not surprising that constant expression 
of TAg would eventually drive changes in the JCPyV genome over time. In a recent study 
looking at viral mutation rates, it was estimated that the mutation rates of DNA viruses 
presented as substitutions per nucleotide per cell infection (s/n/c) ranged from 10-8 to 10-6 s/n/c 
(207). Thus, the chances of mutations occurring in the NCCR of archetype JCPyV would 
increase over time due to the constant driven replication in COS-7 cells, but does not explain 
the mechanism in which in vitro rearrangement occurs. This system has its limitations including 
the length of time to prove rearrangement and utilizing a transformed cell line. Thus, future 
studies will be focused on using agents to induce NCCR rearrangements, such as dimethyl 
fumurate, fingolimod, and leflunomide, all of which have been associated with PML. 
Furthermore, we will identify the point in which this rearrangement occurred by analyzing 
previously frozen lysates by deep sequencing and identifying possible transcription factors that 
contributed to this rearrangement. 
 
Chapter 4 is dedicated to understanding the effect of PML associated JCPyV VP1 mutations on 
JCPyV replication kinetics in HBMVE cells. A discrepancy between the high prevalence of 
JCPyV and the low incidence of PML in the human population suggests the progression from 
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asymptomatic infection to PML could be controlled by a unique viral characteristic. Recent work 
has demonstrated amino acid changes to the viral capsid protein VP1 resulted in accelerated 
evolution in viral sequences isolated form PML patients but not in sequences isolated from 
healthy individuals (225). In addition, VP1 derived virus-like particles (VLP) exhibiting mutations 
resulted in diminished hemagglutination ability, demonstrated different ganglioside specificity, 
and abolished binding to different peripheral cell types compared with wild-type VLPs (87). 
Unfortunately, the limitation to this study was the inability to demonstrate replication of JCPyV 
VP1 mutants in HBMVE cells, and therefore we could not study the loss of hemagglutination 
activity because virus was not produced after transfection. Therefore, it still remains unclear 
whether alterations to JCPyV VP1 will exhibit changes in viral DNA replication activity, infectious 
virus production, and NCCR rearrangement.  
 
The artificial insertion of exogenous viral DNA into cells via transfection is an important, well-
established tool, however, our results highlights the importance in understanding the natural 
process of infection, whereby initial binding of virus might trigger downstream molecules 
important to the JCPyV lifecycle. Utilizing similar methods to propagate urine-derived archetype 
JCPyV, we were able to propagate infectious CY virions to corroborate that CY, like urine-
derived archetype JCPyV, can infect HBMVE cells. Future studies will address this by 
propagating infectious JCPyV VP1 mutant virions by transfecting COS-7 cells, instead of 
HBMVE cells, as seen with our ability to propagate infectious CY virions after transfecting COS-
7 cells. It would be of interest to utilize our established method of propagation to create 
infectious virions for JCPyV VP1 mutants.  
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Lastly, chapter 5 is dedicated to developing an in vivo JCPyV infection animal model. Recently, 
a novel murine model, NOD scid gamma (NSG) reconstituted with human hematopoietic stem 
cells, coined ‘humanized NSG mice’, has been employed to study human-specific pathogens 
(162). 12 weeks after engraftment with human CD34+ hematopoietic stem cells, NSG mice 
display engraftment of mature human white blood cells, human CD45+, including human B 
cells, human CD19+. JCPyV, a human specific pathogen, has been shown to infect human EBV 
transformed B cells (31). Although straightforward, we demonstrated archetype and rearranged 
JCPyV infection in human B cells, albeit at low levels, and excretion of JCPyV DNA in the urine 
of NSG mice. While this model has its limitations, including the inability to demonstrate 
pathogenesis and persistent infection in organs due to the inability of JCPyV to infect murine 
cells, NSG mice could be used as a model to further study JCPyV immune responses and 
infection in the blood. 
 
Future plans 
The scope of this thesis, simply put, was to understand archetype JCPyV infection. This 
objective was satisfied by demonstrating the infection of archetype JCPyV in in vitro and in vivo 
models, delineating the cellular tropism of archetype JCPyV, and trying to understand possible 
mechanisms of reactivation and rearrangement leading to the pathogenic rearranged form of 
JCPyV. To strengthen our findings, future studies are focused on determining the cellular 
factors, including but not limited to, transcription factors and cytidine deaminases, that can 
contribute to JCPyV replication and rearrangement.  
 
To better understand how transcription factors play a role in archetype JCPyV reactivation and 
rearrangement, we will compare and contrast transcription factors that can bind to the NCCR of 
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archetype, Mad-1 rearranged, and D645 rearranged strains of JCPyV by predictive modeling. 
We will determine the expression of transcription factors in JCPyV permissive and non-
permissive cells. Once we identify the transcription factors that contribute to virus reactivation, 
we will employ site-directed mutagenesis of archetype JCPyV NCCR to abrogate the binding of 
transcription factors and siRNA knockdown of transcription factors to demonstrate loss of 
function and disruption of JCPyV replication. 
 
It has been established that cell type specificity of JCPyV within human cells occurs at the 
transcriptional level. The regulation of transcription is dependent on the sequence of the NCCR, 
as well as the availability of host transcription factors, which are the determining factor in both 
the start sites of early transcription, as well as the quantity of TAg produced (70). Unlike other 
human DNA-containing viruses, such as herpesviruses, JCPyV does not bring transcriptional 
activating proteins into newly infected cells. Therefore, although host cell factors are the 
determining factor in directing early transcription, the exact profile of transcription factors 
involved in reactivation and rearrangement remains elusive. 
 
Until now, there has been a crucial need for in vitro systems mimicking JCPyV infection to 
address key questions in JCPyV biology. By understating what cells are conducive to JCPyV 
infection, replication, and reactivation, we can target parts of the JCPyV life cycle for 
therapeutics to prevent or treat PML, including JCPyV TAg and/or host transcription factors that 
are needed to initiate transcription. This dissertation has provided new molecular information for 
understanding JCPyV tropism, archetype JCPyV propagation, and more importantly identified 
key cells conducive to archetype JCPyV infection, which has never been described. Therefore, 
the findings in this dissertation can further advance the field of JCPyV by providing novel 
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insights in establishing physiologically authentic infection models and co-culturing models, (i.e. 
blood-brain barrier model) to test potential therapeutics.  
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